Document:

Exhibit  EX-4.5

SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 28, 2005, by and among ART
Advanced Research Technologies, Inc., a Canadian corporation, with headquarters located at 2300
Alfred-Nobel Blvd., Saint Laurent, Québec, H4S 2A4 Canada (the “Company”), and the investors listed
on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

WHEREAS:

A. The Company and each Buyer is executing and delivering this Agreement in reliance upon the
exemption from (i) securities registration afforded by Section 4(2) of the Securities Act of 1933,
as amended (the “1933 Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the
United States Securities and Exchange Commission (the “SEC”) under the 1933 Act and (ii) prospectus
qualification under the Securities Act (Quebec) (the “Quebec Act”) afforded by Section 51 of the
Quebec Act.

B. The Company has authorized a new series of senior secured convertible notes of the Company,
which notes shall be convertible into the Company’s common stock (the “Common Stock”), in
accordance with the terms of such notes.

C. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and
conditions stated in this Agreement, (i) that aggregate principal amount of notes, in substantially
the form attached hereto as Exhibit A (the “Initial Notes”), set forth opposite such
Buyer’s name in column (3) on the Schedule of Buyers (which aggregate amount for all Buyers shall
be $5,000,000) (as converted into Common Stock, collectively, the “Initial Conversion Shares”),
(ii) warrants, in substantially the form attached hereto as Exhibit B (the “A Warrants”),
to acquire up to that number of additional shares of Common Stock set forth opposite such Buyer’s
name in column (4) of the Schedule of Buyers (as exercised, collectively, the “A Warrant Shares”)
and (iii) warrants, in substantially the form attached hereto as Exhibit C (the “B
Warrants”, and together with the A Warrants, the “Warrants”), to acquire up to that number of
additional shares of Common Stock set forth opposite such Buyer’s name in column (5) of the
Schedule of Buyers (as exercised, collectively, the “B Warrant Shares”, and together with the A
Warrant Shares, the “Warrant Shares”).

D. Subject to the terms and conditions set forth in this Agreement, the Buyers shall have the
right to participate, and in certain circumstances the Company may require the Buyers to
participate, in one or more Additional Closings (as defined in Section 1(a)(ii) below) for the
purchase by the Buyers and the sale by the Company of up to that aggregate principal amount of
notes, in substantially the form attached hereto as Exhibit A (collectively, the
"Additional Notes” and, collectively with the Initial Notes, the “Notes”) set forth opposite such
Buyer’s name in column (6) on the Schedule of Buyers (which aggregate additional amount for all
Buyers shall be $2,500,000) (as converted, collectively, the “Additional Conversion Shares” and,
collectively with the Initial Conversion Shares, the “Conversion Shares”).

E. The Notes bear interest that, at the option of the Company, subject to certain conditions,
may be paid in shares of Common Stock (the “Interest Shares”).

F. The Notes, the Conversion Shares, the Interest Shares, the Warrants and the Warrant Shares
collectively are referred to herein as the “Securities”.

G. The Notes will be (i) senior to all outstanding and future indebtedness of the Company,
(ii) secured by a perfected security interest and hypothec in all of the assets of the Company and
in all of the assets of certain Subsidiaries as evidenced by (and as defined in) the Hypothec
Agreement in favor of Portside Growth & Opportunity Fund, a company organized under the laws of the
Cayman Islands, in its capacity as collateral agent and the person holding the power of attorney
(in such capacity, the “Senior Agent”) for the Buyers hereto and for the other holders of the
Securities, in the form attached hereto as Exhibit H (the “Hypothec Agreement”), which
security interest and hypothec shall be senior to all other security interests therein (other than
Permitted Liens (as defined in the Notes)), and as evidenced by such other security documents as
are necessary and reasonably appropriate, including, without limitation, certain account control
agreements in form and substance reasonably satisfactory to the Senior Agent (the “Account Control
Agreements”), and (iii) guaranteed by the Guarantee of each of its Subsidiaries that is as of the
Closing Date, or thereafter becomes, a party to such Hypothec Agreement, substantially in the form
attached hereto as Exhibit I (the “Guarantees”, together with the Hypothec Agreement, the
Account Control Agreement and such other security documents as are necessary and appropriate,
collectively, the “Security Documents”).

NOW, THEREFORE, the Company and each Buyer hereby agree as follows:

1. PURCHASE AND SALE OF NOTES AND WARRANTS.

(a) Purchase of Notes and Warrants.

(i) Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7
below, the Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly,
agrees to purchase from the Company on the Initial Closing Date (as defined below), (A) one or more
Initial Notes with an aggregate principal amount as is set forth opposite such Buyer’s name in
column (3) on the Schedule of Buyers and (B) one or more Warrants to acquire up to that number of
Warrant Shares as is set forth opposite such Buyer’s name in columns (4) and (5) on the Schedule of
Buyers (the “Initial Closing”). If at the Initial Closing Date any one or more of the Buyers (a
"Refusing Buyer”) shall not complete the purchase of the Initial Notes which it has agreed to
purchase hereunder for any reason whatsoever, the other Buyers (a “Continuing Buyer”) shall have
the right, but shall not be obligated, to purchase the Initial Notes which would otherwise have
been purchased by the Refusing Buyers. If the amount of the Initial Notes which the Continuing
Buyers wish to purchase exceeds the amount of the Initial Notes which would otherwise have been
purchased by the Refusing Buyers, such Initial Notes shall be divided pro rata among the Continuing
Buyers desiring to purchase such Initial Notes in proportion to the percentage of Initial Notes
which such Continuing Buyers have agreed to purchase as set out in the Schedule of Buyers. Nothing
in this section shall oblige the Company to issue and sell to the Buyers less than all of the
Initial Notes to be issued and sold by it or relieve from liability to the Company any Refusing
Buyer which shall be so in default. In the event of a termination by the Company of its
obligations under this Agreement, there shall be no further liability on the part of the Company to
the Buyers.

(ii) Additional Notes. Subject to the satisfaction (or waiver) of the conditions set
forth in Sections 1(c), 6(b) and 7(b) below, at the option of each Buyer, the Company shall issue
and sell to each Buyer, at one or more Additional Closings for the Buyers, and each Buyer
severally, but not jointly, may purchase from the Company on such Additional Closing Date (as
defined below), a principal amount of Additional Notes (the “First Additional Notes Amount”) not to
exceed the aggregate principal amount as is set forth opposite such Buyer’s name in column (6) on
the Schedule of Buyers (each, a “First Additional Closing”) and a principal amount of Additional
Notes (the “Second Additional Notes Amount”) not to exceed the aggregate principal amount as is set
forth opposite such Buyer’s name in column (7) on the Schedule of Buyers (each, a “Second
Additional Closing”, and with the First Additional Closings, each, an “Additional Closing”).

(iii) Closing. The Initial Closing and each Additional Closing are referred to in
this Agreement as a “Closing.” Each shall occur on the applicable Closing Date at the offices of
Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022.

(iv) Purchase Price. The purchase price for each Buyer of the Notes and the Warrants
to be purchased by each such Buyer at the Closing (the “Purchase Price”) shall be the amount set
forth opposite such Buyer’s name in column (8) of the Schedule of Buyers. Each Buyer shall pay
$1.00 for each $1.00 of principal amount of Initial Notes and related Warrants to be purchased by
such Buyer at Initial Closing and shall pay $1.00 for each $1.00 of principal amount of Additional
Notes to be purchased at each Additional Closing.

(b) Initial Closing Date. The date and time of the Initial Closing (the “Initial
Closing Date”) shall be 10:00 a.m., New York City Time, on the date hereof after notification of
satisfaction (or waiver) of the conditions to the Initial Closing set forth in Sections 6(a) and
7(a) below (or such later date as is mutually agreed to by the Company and each Buyer).

(c) Additional Closing Date. (i) The date and time of the Additional Closings (each,
an “Additional Closing Date,” and together with the Initial Closing Date, each a “Closing Date” and
collectively, the “Closing Dates”) shall be 8:00 a.m., New York City Time, on the date specified in
the applicable Additional Closing Notice (as defined below), subject to satisfaction (or waiver) of
the conditions to each Additional Closing set forth in Sections 6(b) and 7(b) and the conditions
contained in this Section 1(c) (or such later date as is mutually agreed to by the Company and the
applicable Buyer). Subject to the requirements of Sections 6(b) and 7(b) and the conditions
contained in this Section 1(c), each Buyer may purchase, at such Buyer’s option, Additional Notes
by delivering written notice to the Company (an “Additional Closing Notice”) at any time (A) with
respect to the First Additional Notes Amount, during the period beginning after the date hereof and
ending on the one year anniversary of the Initial Closing Date (the “First Optional Additional
Notes Notice Termination Date”) and (B) with respect to the Second Additional Notes Amount, during
the period beginning after the date the Shareholder Approval (as defined in Section 4(s) below) has
been obtained and ending one year thereafter (the “Second Optional Additional Notes Notice
Termination Date”, and with the First Optional Additional Notes Notice Termination Date, each an
"Optional Additional Notes Notice Termination Date”); provided, that each Buyer may only
exercise such right once with respect to the First Additional Notes Amount and once with respect to
the Second Additional Notes Amount. In addition to the foregoing, if (x) (A) with respect to the
First Additional Notes Amount, at any time from and after the Initial Closing Date until the one
year anniversary date of the Initial Closing Date or (B) with respect to the Second Additional
Notes Amount, during the period beginning after the date the Shareholder Approval has been obtained
and ending one year thereafter, the Closing Sale Price (as defined in the Notes) of the Common
Stock equals or exceeds CDN$1.485 (subject to appropriate adjustments for stock splits, stock
dividends, stock combinations or other similar transactions after the Initial Closing Date) for
each of any twenty (20) consecutive Trading Days (as defined in the Notes) and (y) the Equity
Conditions (as defined in the Notes) shall have been satisfied (or waived in writing by each
Buyer), on each Trading Day during the period commencing on the date of delivery of the applicable
Mandatory Funding Notice (as defined below), and ending on the applicable Additional Closing Date,
the Company shall have the right to require each Buyer to purchase Additional Notes by delivering
to each Buyer an Additional Closing Notice (as provided by the Company, a “Mandatory Funding
Notice”) setting forth the principal amount of Additional Notes to be purchased by the Buyers,
which principal amount, when added to the principal amount of any Additional Notes previously
purchased by each Buyer shall not exceed (1) if on or prior to the First Optional Additional Notes
Notice Termination Date, but prior to the date the Company obtains the Shareholder Approval, the
First Additional Notes Amount, (2) if on or prior to the First Optional Additional Notes Notice
Termination Date and the Second Additional Notes Notice Termination Date, but after the date the
Company obtains the Shareholder Approval, the aggregate of the First Additional Notes Amount and
the Second Additional Notes Amount, or (3) if after the First Optional Additional Notes Notice
Termination Date and after the date the Company obtains the Shareholder Approval, but prior to the
Second Optional Additional Notes Notice Termination Date, the Second Additional Notes Amount;
provided, that if the Company elects to deliver a Mandatory Funding Notice to any Buyer, it must
deliver a Mandatory Funding Notice requiring the purchase of a pro rata amount of Additional Notes
to all Buyers. Any Mandatory Funding Notice delivered by the Company shall be irrevocable. Each
Mandatory Funding Notice shall contain a proposed Additional Closing Date that shall be at least 10
Business Days but not more than 60 Business Days following the date of delivery of such Mandatory
Funding Notice to the Buyers. An Additional Closing Notice shall be delivered at least five
Business Days prior to the applicable Additional Closing Date set forth in such Additional Closing
Notice. An Additional Closing Notice shall set forth (i) the principal amount of Additional Notes
to be purchased by such Buyer at the applicable Additional Closing, which principal amount, when
added to the principal amount of any Additional Notes previously purchased by such Buyer, shall not
exceed the sum of the First Additional Notes Amount and the Second Additional Notes Amount, (ii)
the aggregate Purchase Price for the Additional Notes to be purchased and (iii) the proposed
Additional Closing Date. The Company shall promptly deliver a copy of each Additional Closing
Notice to each Buyer that did not issue such Additional Closing Notice and allow such Buyer to
participate in such Additional Closing. In the event the Company, (x) as of the First Optional
Additional Notes Notice Termination Date, has not sold $2.0 million in aggregate principal amount
of Additional Notes of the First Additional Notes Amount to the Buyers or (y) as of the Second
Optional Additional Notes Notice Termination Date, has not sold $0.5 million in aggregate principal
amount of Additional Notes of the Second Additional Notes Amount to the Buyers, the Company may
deliver a notice (the “Undersubscription Notice”) to each Buyer that has elected to purchase the
entire First Additional Notes Amount or Second Additional Notes Amount, as applicable, of such
Buyer (the “Additional Basic Amount”) within 5 Business Days of such anniversary notifying them of
the principal amount of Additional Notes that have not been sold, such notice containing an offer
to such Buyers to purchase more Additional Notes by delivering a notice to the Company within 10
Business Days (a “Undersubscription Election Notice”) from their receipt of a Undersubscription
Notice to purchase some or all of the remaining Additional Notes specified in the Undersubscription
Notice (the terms, conditions and purchase price shall be the same as specified with respect to the
sale of the other Additional Notes). The Undersubscription Election Notice shall specify the
principal amount of Additional Notes such Buyer elects to purchase (not to exceed the amount
specified in the Undersubscription Notice). If the total principal amount of Additional Notes
specified in the Undersubscription Election Notices of all Buyers is more than the aggregate
principal amount of Additional Notes specified in the applicable Undersubscription Notice, each
Buyer who has subscribed for any Additional Notes pursuant to an Undersubscription Notice shall be
entitled to purchase only that portion of the amount specified in Undersubscription Notice as the
Additional Basic Amount of such Buyer bears to the total Additional Basic Amounts of all Buyers
that have subscribed for Additional Notes pursuant to an Undersubscription Notice, subject to
rounding by the Company to the extent it deems reasonably necessary. The additional Closing Date
for the Additional Notes to be purchased pursuant to Undersubscription Election Notices shall occur
30 Business Days after the applicable Optional Additional Notice Termination Date. As used herein,
"Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in
The City of New York are authorized or required by law to remain closed.

(d) Form of Payment. On each Closing Date, each Buyer shall pay its Purchase Price to
the Company for the Notes and the Warrants to be issued and sold to such Buyer at such Closing, by
wire transfer of immediately available funds in accordance with the Company’s written wire
instructions; provided, that $2.0 million of the Purchase Price for the Initial Notes shall be paid
by wire transfer of immediately available funds in accordance with the Company’s written wire
transfer instructions into the Cash Collateral Account (as defined below). Within three (3)
Business Days after each Closing Date, the Company shall deliver to each Buyer (A) the Notes
(denominated in the principal amounts as such Buyer shall request) that such Buyer is then
purchasing and (B) the Warrants (denominated in the amounts as such Buyer shall request) such Buyer
is purchasing in each case duly executed on behalf of the Company and registered in the name of
such Buyer or its designee.

2. BUYER’S REPRESENTATIONS AND WARRANTIES.

Each Buyer represents and warrants with respect to only itself that:

(a) No Sale or Distribution. Such Buyer is acquiring the Notes and the Warrants and
upon conversion of the Notes and exercise of the Warrants will acquire the Conversion Shares
issuable upon conversion of the Notes and the Warrant Shares issuable upon exercise of the Warrants
for its own account and not with a view towards, or for resale in connection with, the sale or
distribution thereof, except pursuant to sales registered or exempted under the 1933 Act; provided,
however, that by making the representations herein, such Buyer does not agree to hold any of the
Securities for any minimum or other specific term and reserves the right to dispose of the
Securities at any time in accordance with or pursuant to a registration statement or prospectus, or
an exemption under the 1933 Act and the Quebec Act. Such Buyer is acquiring the Securities
hereunder in the ordinary course of its business. Such Buyer does not presently have any agreement
or understanding, directly or indirectly, with any Person to distribute any of the Securities.

(b) Accredited Investor and $150,000 Minimum Subscription. Such Buyer is Purchaser is
purchasing Notes with an aggregate acquisition cost to it of at least $150,000 and no disclosure
document within the meaning of the Quebec Act and the rules and regulations thereunder has been
delivered in connection with the trade of Notes to the Buyer. Such Buyer is an institutional
“accredited investor” within the meaning of Rule 501(a)(1), (2), (3) or (7) of Regulation D. Such
Buyer is resident in the jurisdiction indicated on the Schedule of Buyers and has made its
investment decision in that jurisdiction or at its address on the Schedule of Buyers.

(c) Reliance on Exemptions. Such Buyer understands that the Securities are being
offered and sold to it in reliance on specific exemptions from the registration requirements of
United States federal and state securities laws and the prospectus requirements of Canadian
Securities Laws (as defined below) and that the Company is relying in part upon the truth and
accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of such Buyer set forth herein in order to determine the
availability of such exemptions and the eligibility of such Buyer to acquire the Securities.

(d) Information. Such Buyer and its advisors, if any, have been furnished with all
materials relating to the business, finances and operations of the Company and materials relating
to the offer and sale of the Securities that have been requested by such Buyer. Such Buyer and its
advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such
inquiries nor any other due diligence investigations conducted by such Buyer or its advisors, if
any, or its representatives shall modify, amend or affect such Buyer’s right to rely on the
Company’s representations and warranties contained herein. Such Buyer understands that its
investment in the Securities involves a high degree of risk. Such Buyer has sought such
accounting, legal and tax advice as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Securities. Such Buyer has sufficient knowledge
and experience in financial and business matters as to be capable of evaluating the merits and
risks of its investment in the Securities and is able to bear the economic risks of such
investment.

(e) No Governmental Review. Such Buyer understands that no United States or Canadian
federal, state or provincial agency or any other government or governmental agency has passed on or
made any recommendation or endorsement of the Securities or the fairness or suitability of the
investment in the Securities nor have such authorities passed upon or endorsed the merits of the
offering of the Securities.

(f) Transfer or Resale. Such Buyer understands that: (i) the Securities have not
been and are not being registered or qualified under the 1933 Act, the Quebec Act or any state or
provincial securities laws, (ii) the Securities may not be offered for sale, sold, assigned or
transferred in the United States or to a U.S. person (within the meaning of Regulation S) unless
(A) such sale is registered under the 1933 Act or (B) such Buyer shall have delivered to the
Company an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that
such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant
to an exemption from such registration, including Rule 144 or Rule 144A promulgated under the 1933
Act, as amended, (or a successor rule thereto); (iii) any sale of the Securities made in reliance
on Rule 144 or Rule 144A may be made only in accordance with the terms thereof and further, if Rule
144 or Rule 144A is not applicable, any resale of the Securities under circumstances in which the
seller (or the Person (as defined in Section 3(s)) through whom the sale is made) may be deemed to
be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other
exemption under the 1933 Act or the rules and regulations of the SEC thereunder; (iv) neither the
Company nor any other Person is under any obligation to register or qualify the Securities by
prospectus under the 1933 Act, the Quebec Act or any provincial or state securities laws or to
comply with the terms and conditions of any exemption thereunder and (v) the Securities may not be
offered for sale, sold, assigned or transferred in Canada or to a person who is a resident of
Canada before November 28, 2005 unless qualified by prospectus or pursuant to an exemption from
such qualification and otherwise any sale or transfer of the Securities to a purchaser or
transferee whose address is in Canada is prohibited unless it is made in compliance with applicable
Canadian Securities Laws (as defined below).

(g) Legends. Such Buyer understands that the certificates or other instruments
representing the Notes and Warrants and the stock certificates representing the Conversion Shares
and the Warrant Shares, except as set forth below, shall bear any legend as required by the “blue
sky” laws of any state and a restrictive legend in substantially the following form (and a
stop-transfer order may be placed against transfer of such stock certificates):

[NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE]
[EXERCISABLE] HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933
ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE
OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED WITHIN THE UNITED STATES OR
TO ANY U.S. PERSON (AS DEFINED IN RULE 902 OF THE 1933 ACT) (I) IN THE
ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL, IN A
FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED
UNDER SAID ACT IN RELIANCE UPON RULE 144 OR RULE 144A UNDER SAID ACT OR
ANOTHER AVAILABLE EXEMPTION. NOTWITHSTANDING THE FOREGOING, THE SECURITIES
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES TOGETHER WITH OTHER
SECURITIES OF THE HOLDER.

The legend set forth above shall be removed and the Company shall issue a certificate without such
legend to the holder of the Securities upon which it is stamped, if, unless otherwise required by
state securities laws, (i) upon a resale of such Securities are that is registered under the 1933
Act, or (ii) in connection with a sale, assignment or other transfer, in which such holder provides
the Company with an opinion of counsel, in a form reasonably acceptable to the Company, to the
effect that such sale, assignment or transfer of the Securities may be made without registration
under the applicable requirements of the 1933 Act in reliance upon Rule 144 or Rule 144A or another
available exemption.

(h) Canadian Legends. Such Buyer understands that the certificates or other
instruments representing the Notes and Warrants and, if the Notes are converted or the Warrants are
exercised prior to November 28, 2005, the stock certificates representing the Conversion Shares and
the Warrant Shares, shall bear the legend set forth below:

“UNLESS PERMITTED UNDER CANADIAN SECURITIES LAWS, THE HOLDER OF THIS SECURITY MUST
NOT TRADE THE SECURITY BEFORE NOVEMBER 28, 2005.”

The legend set forth above shall be removed and the Company shall issue a certificate without such
legend to the holder of the Securities upon which it is stamped in connection with any resale which
occurs after November 28, 2005. The stock certificates representing the Conversion Shares and the
Warrant Shares shall also bear the legend set forth below:

“THE COMMON SHARES REPRESENTED BY THIS CERTIFICATE ARE LISTED ON THE TORONTO STOCK
EXCHANGE (“TSX”); HOWEVER, SAID SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE, AND CONSEQUENTLY ANY CERTIFICATE
REPRESENTING SUCH SHARES IS NOT “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTION ON TSX”

The legends set forth above shall be removed and the Company shall issue a certificate without such
legend to the holder of the Securities upon which it is stamped at such time as no other
restrictive legend appears on such certificate.

(i) Validity; Enforcement. This Agreement and the Security Documents to which such
Buyer is a party have been duly and validly authorized, executed and delivered on behalf of such
Buyer and shall constitute the legal, valid and binding obligations of such Buyer enforceable
against such Buyer in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement
of applicable creditors’ rights and remedies.

(j) No Conflicts. The execution, delivery and performance by such Buyer of this
Agreement and the Security Documents to which such Buyer is a party and the consummation by such
Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation of the
organizational documents of such Buyer or (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or
instrument to which such Buyer is a party, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including U.S. federal and state securities laws)
applicable to such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which would not, individually or in the aggregate, reasonably be
expected to have a material adverse effect on the ability of such Buyer to perform its obligations
hereunder.

(k) Residency. Such Buyer is a resident of that jurisdiction specified below its
address on the Schedule of Buyers.

(l) No Other Representations. Such Buyer shall not be deemed to have made any
representation or warranty other than as expressly set forth in this Agreement or in the other
Transaction Documents.

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

The Company represents and warrants to each of the Buyers that:

(a) Organization and Qualification. The Company and its “Subsidiaries” (which for
purposes of this Agreement means any entity in which the Company, directly or indirectly, owns 50%
or more of the outstanding capital stock or holds an equity or similar interest representing 50% or
more of the outstanding equity or similar interest of such entity) are entities duly organized and
validly existing and in good standing under the laws of the jurisdiction in which they are formed,
and have the requisite power and authorization to own their properties and to carry on their
business as now being conducted. Each of the Company and its Subsidiaries is duly qualified as a
foreign or extra-provincial entity to do business and, to the extent legally applicable, is in good
standing in every jurisdiction in which its ownership of property or the nature of the business
conducted by it makes such qualification necessary, except to the extent that the failure to be so
qualified or be in good standing would not have a Material Adverse Effect. As used in this
Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties,
assets, operations, results of operations, condition (financial or otherwise) or prospects of the
Company and its Subsidiaries, taken as a whole, or on the transactions contemplated hereby and in
the Security Documents or by the agreements and instruments to be entered into in connection
herewith or therewith, or on the authority or ability of the Company to perform its obligations
under the Transaction Documents (as defined below). The Company does not hold any equity or
similar interest in any entity except as set forth on Schedule 3(a).

(b) Authorization; Enforcement; Validity. The Company has the requisite power and
authority to enter into and perform its obligations under this Agreement, the Notes, the Security
Documents, the Irrevocable Transfer Agent Instructions (as defined in Section 5(b)), the Warrants
and each of the other agreements entered into by the parties hereto in connection with the
transactions contemplated by this Agreement (collectively, the “Transaction Documents”) and to
issue the Securities in accordance with the terms hereof and thereof. The execution and delivery
of the Transaction Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby, including, without limitation, the issuance of the Notes and the
Warrants and the issuance of the Conversion Shares issuable upon conversion of the Notes, the
issuance of Warrant Shares issuable upon exercise of the Warrants, and the granting of a security
interest in the Collateral (as defined in the Security Documents) have been duly authorized by the
Company’s Board of Directors and, other than the filings specified in Section 3(e), no further
filing, consent, or authorization is required by the Company, its Board of Directors or its
shareholders. This Agreement and the other Transaction Documents of even date herewith have been
duly executed and delivered by the Company, and constitute the legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with their respective terms, except
as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally, the enforcement of applicable creditors’ rights and remedies. As of the date of
issuance of any Additional Notes, such Additional Notes shall have been duly executed and delivered
by the Company, and shall constitute the legal, valid and binding obligations of the Company,
enforceable against the Company in accordance with their respective terms, except as such
enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the
enforcement of applicable creditor’s rights and remedies.

(c) Issuance of Securities. The issuance of the Notes and the Warrants are duly
authorized and are free from all taxes, liens and charges with respect to the issue thereof. As of
each applicable Closing, an unlimited number of shares of Common Stock shall have been duly
authorized and reserved for issuance. Upon issuance or conversion in accordance with the Notes or
exercise in accordance with the Warrants, as the case may be, the Interest Shares, the Conversion
Shares and the Warrant Shares, respectively, will be validly issued, fully paid and non-assessable
and free from all preemptive or similar rights, taxes, liens and charges with respect to the issue
thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.
Assuming the accuracy of each of the representations and warranties set forth in Section 2 of this
Agreement, the offer and issuance by the Company of the Securities is exempt from registration
under the 1933 Act and from the prospectus and registration requirements of applicable Canadian
Securities Laws.

(d) No Conflicts. The execution, delivery and performance of the Transaction
Documents by the Company and the consummation by the Company of the transactions contemplated
hereby and thereby (including, without limitation, the issuance of the Notes and the Warrants, the
granting of a security interest in the Collateral (as defined in the Security Documents) and
issuance of the Interest Shares, the Conversion Shares and the Warrant Shares) will not (i) result
in a violation of any certificate of incorporation, certificate of formation, any certificate of
designations or other constituent documents of the Company or any of is Subsidiaries, any capital
stock of the Company or any of its Subsidiaries or bylaws of the Company or any of its Subsidiaries
or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or
both would become a default) in any material respect under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any material agreement, indenture or
instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a
violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state
securities laws or Canadian Securities Laws and regulations and the rules and regulations of the
Toronto Stock Exchange (the “Principal Market”)) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound
or affected.

(e) Consents. Except as set forth on Schedule 3(e), the Company is not
required to obtain any consent, authorization or order of, or make any filing or registration with,
any court, governmental agency or any regulatory or self-regulatory agency or any other Person in
order for it to execute, deliver or perform any of its obligations under or contemplated by the
Transaction Documents, in each case in accordance with the terms hereof or thereof, except for the
following consents, authorizations, orders, filings and registrations (none of which is required to
be filed or obtained before the Closing): (i) the filing of appropriate filings, registrations and
notices of registration at the appropriate registers and with the appropriate authorities pursuant
to the Security Agreements, (ii) the filing of a listing application for the Conversion Shares,
Interest Shares and Warrant Shares with the Principal Market, which shall be done pursuant to the
rules of the Principal Market and (iii) the filing of requisite filings and notices and payment of
applicable filing fees with Canadian securities regulators. The Company and its Subsidiaries are
unaware of any facts or circumstances that might prevent the Company from obtaining or effecting
any of the registration, application or filings pursuant to the preceding sentence. The Company is
not in violation of the listing requirements of the Principal Market and has no knowledge of any
facts that would reasonably lead to delisting or suspension of the Common Stock in the foreseeable
future.

(f) Acknowledgment Regarding Buyer’s Purchase of Securities. The Company acknowledges
that no Buyer is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated hereby and
thereby, and any advice given by a Buyer or any of its representatives or agents in connection with
the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to such Buyer’s purchase of the Securities. The Company further represents to each Buyer that the
Company’s decision to enter into the Transaction Documents has been based solely on the independent
evaluation by the Company and its representatives.

(g) No General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of
its affiliates, nor any Person acting on its or their behalf, has engaged in any form of general
solicitation or general advertising (including within the meaning of Regulation D) in connection
with the offer or sale of the Securities. The Company shall be responsible for the payment of any
placement agent’s fees, financial advisory fees, or brokers’ commissions (other than for persons
engaged by any Buyer or its investment advisor) relating to or arising out of the transactions
contemplated hereby. The Company shall pay, and hold each Buyer harmless against, any liability,
loss or expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising
in connection with any such claim. The Company acknowledges that it has engaged Winchester Capital
as placement agent (the “Agent”) in connection with the sale of the Securities. Other than the
Agent, the Company has not engaged any placement agent or other agent in connection with the sale
of the Securities.

(h) No Integrated Offering. None of the Company, its Subsidiaries, any of their
affiliates, and any Person acting on their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would
require registration of any of the Securities under the 1933 Act or cause this offering of the
Securities to be integrated with prior offerings by the Company for purposes of the 1933 Act or any
applicable shareholder approval provisions, including, without limitation, under the rules and
regulations of any exchange or automated quotation system on which any of the securities of the
Company are listed or designated. None of the Company, its Subsidiaries, their affiliates and any
Person acting on their behalf will take any action or steps referred to in the preceding sentence
that would require registration of any of the Securities under the 1933 Act or cause the offering
of the Securities to be integrated with other offerings.

(i) Dilutive Effect. The Company understands and acknowledges that the number of
Conversion Shares issuable upon conversion of the Notes and the Warrant Shares issuable upon
exercise of the Warrants will increase in certain circumstances. The Company further acknowledges
that its obligation to issue Conversion Shares upon conversion of the Notes in accordance with this
Agreement and the Notes and its obligation to issue the Warrant Shares upon exercise of the
Warrants in accordance with this Agreement and the Warrants is, in each case, absolute and
unconditional regardless of the dilutive effect that such issuance may have on the ownership
interests of other shareholders of the Company.

(j) Application of Takeover Protections; Rights Agreement. The Company and its board
of directors have taken all necessary action, if any, in order to render inapplicable any control
share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the
laws of the jurisdiction of its formation which is or could become applicable to any Buyer as a
result of the transactions contemplated by this Agreement, including, without limitation, the
Company’s issuance of the Securities and any Buyer’s ownership of the Securities. The Company has
not adopted a shareholder rights plan or similar arrangement relating to accumulations of
beneficial ownership of Common Stock or a change in control of the Company.

(k) SEC-CSA Documents; Financial Statements. During the two (2) years prior to the
date hereof, the Company has filed all reports, schedules, forms, statements and other documents
required to be filed by it with the SEC and the Canadian Securities Administrators (the “CSA”)
pursuant to the reporting requirements of the 1934 Act and the Securities legislation and
regulations of, and the instruments, policies, rules, orders, codes, notices and published
interpretation notes of, the securities regulatory authorities of the provinces and territories of
Canada (the “Canadian Securities Laws”), and no such disclosure has been made on a confidential
basis that remains subject to confidentiality (all of the foregoing filed prior to the date hereof
and all exhibits included therein and financial statements, notes and schedules thereto and
documents incorporated by reference therein being hereinafter referred to as the “SEC-CSA
Documents”). The Company has delivered to the Buyers or their respective representatives true,
correct and complete copies of any of the SEC-CSA Documents not available on the EDGAR and SEDAR
systems. As of their respective dates, the SEC-CSA Documents complied in all material respects
with the requirements of the 1934 Act and the Canadian Securities Laws and the rules and
regulations of the SEC and the CSA promulgated thereunder applicable to the SEC-CSA Documents, and
none of the SEC-CSA Documents, at the time they were filed with the SEC or the CSA as applicable,
contained any untrue statement of a material fact or omitted to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. As of their respective dates, the
financial statements of the Company included in the SEC-CSA Documents complied as to form in all
material respects with applicable accounting requirements and the published rules and regulations
of the SEC and the CSA with respect thereto. Such financial statements have been prepared in
accordance with generally accepted accounting principles in Canada, consistently applied, during
the periods involved (except (i) as may be otherwise indicated in such financial statements or the
notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude
footnotes or may be condensed or summary statements) and fairly present in all material respects
the financial position of the Company as of the dates thereof and the results of its operations and
cash flows for the periods then ended (subject, in the case of unaudited statements, to normal
year-end audit adjustments). No other information provided by or on behalf of the Company to the
Buyers which is not included in the SEC-CSA Documents, including, without limitation, information
referred to in Section 2(d) of this Agreement, contains any untrue statement of a material fact or
omits to state any material fact necessary in order to make the statements therein, in the light of
the circumstance under which they are or were made, not misleading.

(l) Absence of Certain Changes. Since December 31, 2004, there has been no material
adverse change and no material adverse development in the business, properties, operations,
condition (financial or otherwise), results of operations or prospects of the Company or its
Subsidiaries. Except as disclosed in Schedule 3(l), since December 31, 2004, the Company
has not (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate,
in excess of $100,000 outside of the ordinary course of business or (iii) had capital expenditures
individually in excess of $100,000, or in the aggregate in excess of $250,000. The Company has not
taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any
knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy
proceedings or any actual knowledge of any fact that would reasonably lead a creditor to do so.
Except as disclosed in Schedule 3(l), the Company and its Subsidiaries, individually and on
a consolidated basis, are not as of the date hereof, and after giving effect to the transactions
contemplated hereby to occur at the Closing, will not be Insolvent (as defined below). For
purposes of this Section 3(l), “Insolvent” means, with respect to any Person (as defined in Section
3(s)), (i) the present fair saleable value of such Person’s assets is less than the amount required
to pay such Person’s total Indebtedness (as defined in Section 3(s)), or (ii) the Company is unable
to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and
liabilities become absolute and matured.

(m) No Undisclosed Events, Liabilities, Developments or Circumstances. No event,
liability, development or circumstance has occurred or exists, or is contemplated to occur with
respect to the Company or its Subsidiaries or their respective business, properties, prospects,
operations or financial condition, that would be required to be disclosed by the Company under
applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to
an issuance and sale by the Company of its Common Stock or in a material change report under
Canadian Securities Laws and which has not been publicly announced.

(n) Conduct of Business; Regulatory Permits. Neither the Company nor its Subsidiaries
is in violation of any term of or in default under its Certificate of Incorporation or Bylaws or
their organizational charter or certificate of incorporation or bylaws, respectively. Neither the
Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any
statute, ordinance, rule or regulation applicable to the Company or its Subsidiaries, and neither
the Company nor any of its Subsidiaries will conduct its business in violation of any of the
foregoing, except for possible violations that would not, individually or in the aggregate, have a
Material Adverse Effect. Without limiting the generality of the foregoing, the Company is not in
violation of any of the rules, regulations or requirements of the Principal Market and has no
knowledge of any facts or circumstances that would reasonably lead to delisting or suspension of
the Common Stock by the Principal Market in the foreseeable future. Since December 31, 2003, (i)
the Common Stock has been designated for quotation on the Principal Market, (ii) trading in the
Common Stock has not been suspended by the SEC, the CSA or the Principal Market and (iii) the
Company has received no communication, written or oral, from the SEC, the CSA or the Principal
Market regarding the suspension or delisting of the Common Stock from the Principal Market. The
Company and its Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate regulatory authorities necessary to conduct their respective businesses, except where
the failure to possess such certificates, authorizations or permits would not have, individually or
in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has
received any notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit. The Company is a reporting issuer in good standing under the
applicable Canadian Securities Laws.

(o) Foreign Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor
any director, officer, agent, employee or other Person acting on behalf of the Company or any of
its Subsidiaries has, in the course of its actions for, or on behalf of, the Company (i) used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses
relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or
domestic government official or employee from corporate funds; (iii) violated or is in violation of
any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the Corruption of
Foreign Public Officials Act, as amended or (iv) made any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment to any foreign or domestic government official or
employee.

(p) Transactions With Affiliates. Except as set forth in the SEC-CSA Documents filed
at least ten days prior to the date hereof and other than the grant of stock options disclosed on
Schedule 3(p), none of the officers, directors or employees of the Company is presently a
party to any transaction with the Company or any of its Subsidiaries (other than for ordinary
course services as employees, officers or directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, or otherwise requiring payments to or from any such officer, director
or employee or, to the knowledge of the Company, any corporation, partnership, trust or other
entity in which any such officer, director, or employee has a substantial interest or is an
officer, director, trustee or partner.

(q) Equity Capitalization. As of the date hereof, the authorized capital stock of the
Company consists of (i) an unlimited number of Common Stock, of which as of the date hereof,
42,664,523 are issued and outstanding, 4,563,486 shares are reserved for issuance pursuant to the
Company’s stock option and purchase plans and 13,636,470 shares are reserved for issuance pursuant
to securities (other than the Notes and the Warrants) exercisable or exchangeable for, or
convertible into, Common Stock and (ii) an unlimited number of preferred shares, without par value,
of which as of the date hereof 6,341,982 shares of which is issued and outstanding or reserved for
issuance. All of such outstanding shares have been, or upon issuance will be, validly issued and
are fully paid and non-assessable. Except as disclosed in Schedule 3(q): (i) none of the
Company’s share capital is subject to preemptive rights or any other similar rights or any liens or
encumbrances suffered or permitted by the Company; (ii) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, or exercisable or exchangeable for, any share capital of the
Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by
which the Company or any of its Subsidiaries is or may become bound to issue additional share
capital of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities or rights
convertible into, or exercisable or exchangeable for, any share capital of the Company or any of
its Subsidiaries; (iii) there are no outstanding debt securities, notes, credit agreements, credit
facilities or other agreements, documents or instruments evidencing Indebtedness (as defined in
Section 3(r)) of the Company or any of its Subsidiaries or by which the Company or any of its
Subsidiaries is or may become bound; (iv) there are no financing statements securing obligations in
any material amounts, either singly or in the aggregate, filed in connection with the Company; (v)
there are no agreements or arrangements under which the Company or any of its Subsidiaries is
obligated to register the sale of any of their securities under the 1933 Act or under any
applicable Canadian Securities Laws; (vi) there are no outstanding securities or instruments of the
Company or any of its Subsidiaries which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries;
(vii) there are no securities or instruments containing anti-dilution or similar provisions that
will be triggered by the issuance of the Securities; (viii) the Company does not have any stock
appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement; and
(ix) the Company and its Subsidiaries have no liabilities or obligations required to be disclosed
in the SEC-CSA Documents but not so disclosed in the SEC-CSA Documents, other than those incurred
in the ordinary course of the Company’s or its Subsidiaries’ respective businesses and which,
individually or in the aggregate, do not or would not have a Material Adverse Effect. The Company
has made available to the Buyer true, correct and complete copies of the Company’s Certificate of
Incorporation, as amended and as in effect on the date hereof (the “Certificate of Incorporation”),
and the Company’s Bylaws, as amended and as in effect on the date hereof (the “Bylaws”), and the
terms of all securities convertible into, or exercisable or exchangeable for, shares of Common
Stock and the material rights of the holders thereof in respect thereto.

(r) Indebtedness and Other Contracts. Except as disclosed in Schedule 3(r),
neither the Company nor any of its Subsidiaries (i) has any outstanding Indebtedness (as defined
below), (ii) is a party to any contract, agreement or instrument, the violation of which, or
default under which, by the other party(ies) to such contract, agreement or instrument could
reasonably be expected to result in a Material Adverse Effect, (iii) is in violation of any term of
or in default under any contract, agreement or instrument relating to any Indebtedness, except
where such violations and defaults would not result, individually or in the aggregate, in a
Material Adverse Effect, or (iv) is a party to any contract, agreement or instrument relating to
any Indebtedness, the performance of which, in the judgment of the Company’s officers, has or is
expected to have a Material Adverse Effect. Schedule 3(r) provides a detailed description
of the material terms of any such outstanding Indebtedness. For purposes of this Agreement: (x)
"Indebtedness” of any Person means, without duplication (A) all indebtedness for borrowed money,
(B) all obligations issued, undertaken or assumed as the deferred purchase price of property or
services, including (without limitation) “capital leases” in accordance with generally accepted
accounting principles (other than trade payables entered into in the ordinary course of business),
(C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and
other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar
instruments, including obligations so evidenced incurred in connection with the acquisition of
property, assets or businesses, (E) all indebtedness created or arising under any conditional sale
or other title retention agreement, or incurred as financing, in either case with respect to any
property or assets acquired with the proceeds of such indebtedness (even though the rights and
remedies of the seller or bank under such agreement in the event of default are limited to
repossession or sale of such property), (F) all monetary obligations under any leasing or similar
arrangement which, in connection with generally accepted accounting principles, consistently
applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness
referred to in clauses (A) through (F) above secured by (or for which the holder of such
Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien,
pledge, charge, security interest or other encumbrance upon or in any property or assets (including
accounts and contract rights) owned by any Person, even though the Person which owns such assets or
property has not assumed or become liable for the payment of such indebtedness, and (H) all
Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to
in clauses (A) through (G) above; (y) “Contingent Obligation” means, as to any Person, any direct
or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness,
lease, dividend or other obligation of another Person if the primary purpose or intent of the
Person incurring such liability, or the primary effect thereof, is to provide assurance to the
obligee of such liability that such liability will be paid or discharged, or that any agreements
relating thereto will be complied with, or that the holders of such liability will be protected (in
whole or in part) against loss with respect thereto; and (z) “Person” means an individual, a
limited liability company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization and a government or any department or agency thereof.

(s) Absence of Litigation. Except as set forth in Schedule 3(s), there is no
action, suit, proceeding, inquiry or investigation before or by the Principal Market, any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge
of the Company, threatened against or affecting the Company, the Common Stock or any of the
Company’s Subsidiaries or any of the Company’s or the Company’s Subsidiaries’ officers or directors
in their capacities as such.

(t) Insurance. The Company and each of its Subsidiaries are insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as management
of the Company believes to be prudent and customary in the businesses in which the Company and its
Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any
insurance coverage sought or applied for and neither the Company nor any such Subsidiary has any
reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.

(u) Employee Relations. (i) Neither the Company nor any of its Subsidiaries is a
party to any collective bargaining agreement or employs any member of a union. The Company and its
Subsidiaries believe that their relations with their employees are good. No executive officer of
the Company (as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer
intends to leave the Company or otherwise terminate such officer’s employment with the Company. No
executive officer of the Company, is, or is now expected to be, in violation of any material term
of any employment contract, confidentiality, disclosure or proprietary information agreement,
non-competition agreement, or any other contract or agreement or any restrictive covenant, and the
continued employment of each such executive officer does not subject the Company or any of its
Subsidiaries to any liability with respect to any of the foregoing matters.

(ii) The Company and its Subsidiaries are in compliance with all United States and Canadian
federal, state, provincial, local and foreign laws and regulations respecting labor, employment and
employment practices and benefits, terms and conditions of employment and wages and hours, except
where failure to be in compliance would not, either individually or in the aggregate, reasonably be
expected to result in a Material Adverse Effect.

(v) Title. The Company and its Subsidiaries have good and marketable title to all
real and personal, movable and immovable property owned by them which is material to the business
of the Company and its Subsidiaries, in each case free and clear of all liens, charges, hypothecs,
encumbrances and defects except such as do not materially affect the value of such property and do
not interfere with the use made and proposed to be made of such property by the Company and any of
its Subsidiaries. Any real property and facilities held under lease by the Company and any of its
Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property
and buildings by the Company and its Subsidiaries.

(w) Intellectual Property Rights. The Company and its Subsidiaries own or possess
adequate rights or licenses to use all trademarks, service marks and all applications and
registrations therefor, trade names, patents, patent rights, copyrights, original works of
authorship, inventions, trade secrets, licenses, approvals, governmental authorizations and other
intellectual property rights (“Intellectual Property Rights”) necessary to conduct their respective
businesses as now conducted. Except as set forth in Schedule 3(w), none of the Company’s
Intellectual Property Rights have expired, terminated or have been abandoned, or are expected to
expire, terminate or be abandoned, within three years from the date of this Agreement. The Company
does not have any knowledge of any infringement by the Company or its Subsidiaries of Intellectual
Property Rights of others. There is no claim, action or proceeding being made or brought, or to
the knowledge of the Company, being threatened against the Company or its Subsidiaries regarding
its Intellectual Property Rights. The Company is unaware of any facts or circumstances which might
give rise to any of the foregoing infringements or claims, actions or proceedings. The Company and
its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality
and value of all of their Intellectual Property Rights.

(x) Environmental Laws. The Company and its Subsidiaries (i) are in compliance with
any and all Environmental Laws (as hereinafter defined), (ii) have received all permits, licenses
or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses and (iii) are in compliance with all terms and conditions of any such permit, license or
approval where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply
could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.
The term “Environmental Laws” means all United States and Canadian federal, state, provincial,
local or foreign laws relating to pollution or protection of human health or the environment
(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface
strata), including, without limitation, laws relating to emissions, discharges, releases or
threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or
wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters,
injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations
issued, entered, promulgated or approved thereunder.

(y) Subsidiary Rights. Except as set forth in Schedule 3(y), the Company or
one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by
applicable law) to receive dividends and distributions on, all capital securities of its
Subsidiaries as owned by the Company or such Subsidiary.

(z) Tax Status. Except as set forth in Schedule 3(z), the Company and each of
its Subsidiaries (i) has made or filed all foreign, United States and Canadian federal, state and
provincial income and all other tax returns, reports and declarations required by any jurisdiction
to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that
are material in amount, shown or determined to be due on such returns, reports and declarations,
except those being contested in good faith and (iii) has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which
such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know
of no basis for any such claim.

(aa) Internal Accounting and Disclosure Controls. The Company and each of its
Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset and
liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in
accordance with management’s general or specific authorization and (iv) the recorded accountability
for assets and liabilities is compared with the existing assets and liabilities at reasonable
intervals and appropriate action is taken with respect to any difference. The Company maintains
disclosure controls and procedures (as such term is defined in Rule 13a-14 under the 1934 Act) that
are effective in ensuring that information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within
the time periods specified in the rules and forms of the SEC, including, without limitation,
controls and procedures designed in to ensure that information required to be disclosed by the
Company in the reports that it files or submits under the 1934 Act is accumulated and communicated
to the Company’s management, including its principal executive officer or officers and its
principal financial officer or officers, as appropriate, to allow timely decisions regarding
required disclosure.

(bb) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other
relationship between the Company and an unconsolidated or other off balance sheet entity that is
required to be disclosed by the Company in its Exchange Act filings and is not so disclosed or that
otherwise would be reasonably likely to have a Material Adverse Effect.

(cc) Ranking of Notes. Except for Indebtedness that will be cancelled at the Initial
Closing, no Indebtedness of the Company is senior to or ranks pari passu with the Notes in right of
payment, whether with respect of payment of redemptions, interest, damages or upon liquidation or
dissolution or otherwise.

(dd) Share Freely Tradeable. From and after November 28, 2005, the Conversion Shares,
the Warrant Shares and any Interest Shares to be issued, may be resold on the Principal Market, in
each case: (A) subject to compliance with the requirements of the 1933 Act by a U.S. Holder, if
applicable; and (B) subject to compliance with the conditions of Section 2.5 of Multilateral
Instrument 45-102 of the Canadian Securities Administrators and the corresponding requirements of
Quebec Securities Laws.

(ee) Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other
than income or similar taxes) which are required to be paid in connection with the sale and
transfer of the Securities to be sold to each Buyer hereunder will be, or will have been, fully
paid or provided for by the Company, and all laws imposing such taxes will be or will have been
complied with.

(ff) Acknowledgement Regarding Buyers’ Trading Activity. Anything in this Agreement
or elsewhere herein to the contrary notwithstanding, it is understood and acknowledged by the
Company (i) that none of the Buyers have been asked to agree, nor has any Buyer agreed, to desist
from purchasing or selling, long and/or short, securities of the Company, or “derivative”
securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) that any Buyer, and counter parties in “derivative” transactions to which any such Buyer
is a party, directly or indirectly, presently may have a “short” position in the Common Stock, and
(iii) that each Buyer shall not be deemed to have any affiliation with or control over any arm’s
length counter-party in any “derivative” transaction. The Company further understands and
acknowledges that one or more Buyers may engage in hedging activities at various times during the
period that the Securities are outstanding, including, without limitation, during the periods that
the value of the Conversion Shares, the Warrant Shares and Interest Shares deliverable with respect
to Securities are being determined.

(gg) Manipulation of Price. The Company has not, and to its knowledge no one acting
on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in
the stabilization or manipulation of the price of any security of the Company to facilitate the
sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any person
any compensation for soliciting another to purchase any other securities of the Company.

(hh) Disclosure. The Company confirms that neither it nor any other Person acting on
its behalf has provided any of the Buyers or their agents or counsel with any information that
constitutes or could reasonably be expected to constitute material, nonpublic information. The
Company understands and confirms that each of the Buyers will rely on the foregoing representations
in effecting transactions in securities of the Company. The Transaction Documents, including the
Schedules to this Agreement are true and correct and do not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not misleading. No event or
circumstance has occurred or information exists with respect to the Company or any of its
Subsidiaries or its or their business, properties, prospects, operations or financial conditions,
which, under applicable law, rule or regulation, requires public disclosure or announcement by the
Company but which has not been so publicly announced or disclosed.

(ii) Bank Accounts. The Company represents and warrants that all accounts of the
Company with banks or other financial entities are located in Montreal, Quebec.

(jj) No Other Representations. The Company and its Subsidiaries shall not be deemed
to have made any representation or warranty other than as expressly set forth in this Agreement or
in the other Transaction Documents.

4. COVENANTS.

(a) Reasonable Best Efforts; Cooperation.

(i) Each party shall use its reasonable best efforts timely to satisfy each of the conditions
to be satisfied by it as provided in Sections 6 and 7 of this Agreement.

(ii) The parties hereto agree to reasonably cooperate with each other after the Initial
Closing to mitigate any adverse effects to the Company or any Buyer of Section 25(c) of the Note,
provided, however, that nothing in this Section 4(a)(ii) shall either (1) obligate any Buyer to
take any other action which such Buyer believes to be adverse to such Buyer or (2) obligate the
Company to take any other action which the Company believes to be adverse to the Company.

(b) Form D and Blue Sky. The Company agrees to file a Form D with respect to the
Securities as required under Regulation D and to provide a copy thereof to each Buyer promptly
after such filing. The Company shall, on or before the Closing Date, take such action as the
Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify
the Securities for sale to the Buyers at the Closing pursuant to this Agreement under applicable
securities or “Blue Sky” laws of the states of the United States and Canadian Securities Law (or to
obtain an exemption from such qualification), and shall provide evidence of any such action so
taken to the Buyers on or prior to each Closing Date. The Company shall file the form prescribed
by Section 51 of the Quebec Act with the Autorité des Marchés Financiers with respect to the
Securities. The Company shall make all filings and reports relating to the offer and sale of the
Securities required under applicable securities or “Blue Sky” laws of the states of the United
States and the applicable Canadian Securities Laws following each such Closing Date.

(c) Reporting Status. Until the date on which the Buyers shall have sold all the
Conversion Shares, Warrant Shares and Interest Shares and none of the Notes or Warrants is
outstanding (the “Reporting Period”), the Company shall timely file all reports required to be
filed by a foreign private issuer with the SEC pursuant to the 1934 Act and applicable securities
regulators under applicable Canadian Securities Laws.

(d) Use of Proceeds. The Company will use the net proceeds from the sale of the
Securities for the clinical development and trials for SoftScan with the balance to be used for new
eXplore Optix enhancements and product extensions. The Company will not use the proceeds from the
sale of the Securities for the (i) repayment of any other outstanding Indebtedness of the Company
or any of its Subsidiaries or (ii) redemption or repurchase of any of its equity securities.

(e) Financial Information. The Company agrees to send the following to each Buyer
during the Reporting Period unless the following are filed with the SEC or the CSA through EDGAR or
SEDAR and are available to the public through the EDGAR or SEDAR systems, within one (1) Business
Day after the filing thereof with the SEC or the CSA, a copy of its Annual Report (on Form 20-F, or
such other form as may be available, in the United States), quarterly financial statements and any
other current reports on Form 6-K in the United States, any material change reports filed under
National Instrument 5I-102 of the CSA and any registration statements (other than on Form S-8) or
amendments filed pursuant to the 1933 Act or prospectus filed pursuant to Canadian Securities Laws.

(f) Listing. The Company shall promptly secure the listing of all of the Conversion
Shares, Warrant Shares and Interest Shares upon each national securities exchange and automated
quotation system, if any, upon which the Common Stock is then listed (subject to official notice of
issuance) and shall maintain such listing of all Conversion Shares, Warrant Shares and Interest
Shares from time to time issuable under the terms of the Transaction Documents. The Company shall
maintain the Common Stocks’ authorization for quotation on the Principal Market. Neither the
Company nor any of its Subsidiaries shall take any action which would be reasonably expected to
result in the delisting or suspension of the Common Stock on the Principal Market;
provided, however, that the Company makes no covenant regarding the trading price
of the Common Stock. The Company shall pay all fees and expenses in connection with satisfying its
obligations under this Section 4(f).

(g) Fees. Subject to Section 8 below, at the Closing, the Company shall pay an
expense allowance to Portside Growth & Opportunity Fund (a Buyer) or its designee(s) (in addition
to any other expense amounts paid to any Buyer prior to the date of this Agreement) to cover
expenses reasonably incurred by Portside Growth & Opportunity Fund or any professionals engaged by
Portside Growth & Opportunity Fund in relation to due diligence and investment documentation, in an
amount not to exceed $75,000 (in addition to any other expense amounts paid to any Buyer prior to
the date of this Agreement), which amount shall be withheld by such Buyer from its Purchase Price
at the Closing. The Company shall also reimburse Portside Growth & Opportunity Fund for the
reasonable costs of performing UCC/personal property security, tax and judgment lien searches and
searches with the Canadian Trade-Mark Office, the Canadian Patent Office, United States Patent and
Trademark Office which costs shall not be deducted from the expense reimbursement set forth in the
immediately preceding sentence. The Company shall be responsible for the payment of any placement
agent’s fees, financial advisory fees, or broker’s commissions (other than for Persons engaged by
any Buyer) relating to or arising out of the transactions contemplated hereby, including, without
limitation, any fees or commissions payable to the Agent. The Company shall pay, and hold each
Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable
attorney’s fees and out-of-pocket expenses) arising in connection with any claim relating to any
such payment. Except as otherwise set forth in the Transaction Documents, each party to this
Agreement shall bear its own expenses in connection with the sale of the Securities to the Buyers.

(h) Pledge of Securities. The Company acknowledges and agrees that the Securities may
be pledged by a Buyer or its successor and assigns in connection with a bona fide margin agreement
or other loan or financing arrangement that is secured by the Securities and no Buyer, successor or
assign thereof effecting a pledge of Securities shall be required to provide the Company with any
notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any
other Transaction Document, including, without limitation, Section 2(f) hereof; provided that a
Buyer and its pledgee shall be required to comply with the provisions of Section 2(f) hereof in
order to effect a sale, transfer or assignment of Securities to such pledgee. The Company hereby
agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably
request in connection with a pledge of the Securities to such pledgee by a Buyer, subject to
compliance with the terms of this Agreement.

(i) Disclosure of Transactions and Other Material Information. On or before 8:30
a.m., New York time, on the first Business Day following the date of this Agreement, the Company
shall file a Current Report on Form 6-K describing the terms of the transactions contemplated by
the Transaction Documents in the form required by the 1934 Act and attaching the material
Transaction Documents (including, without limitation, this Agreement (and all schedules to this
Agreement), the form of each of the Notes, the forms of Warrants and the Security Documents) as
exhibits to such filing (including all attachments, the “Initial 6-K Filing”) and a material change
report on Form 51-102F3 in accordance with National Instrument 51-102 of the CSA with respect
thereto (the “Material Change Report”). On or before 8:30 a.m., New York City Time, on the
Business Day following each Additional Closing Date, the Company shall file a Current Report on
Form 6-K with the SEC describing the transaction consummated on such date (the “Additional 6-K
Filing,” and together with the Initial 6-K Filing, the “6-K Filings”) and a Material Change Report
with respect thereto. From and after the filing of the Initial 6-K Filing with the SEC and the
initial Material Change Report with the CSA, no Buyer shall be in possession of any material,
nonpublic information received from the Company, any of its Subsidiaries or any of its respective
officers, directors, employees or agents, that is not disclosed in the Initial 6-K Filing and the
initial Material Change Report. The Company shall not, and shall cause each of its Subsidiaries
and its and each of their respective officers, directors, employees and agents, not to, provide any
Buyer with any material, nonpublic information regarding the Company or any of its Subsidiaries
from and after the filing of the Initial 6-K Filing with the SEC and the initial Material Change
Report with the CSA without the express written consent of such Buyer. If a Buyer has, or believes
it has, received any such material, nonpublic information regarding the Company or any of its
Subsidiaries, it shall provide the Company with written notice thereof. The Company shall
forthwith following receipt of such notice, make public disclosure of such material, nonpublic
information, but in no event later than ten (10) Trading Days after receipt of such notice,
provided that the Buyer received such material, non public information from the Company. In the
event of a breach of the foregoing covenant by the Company, any of its Subsidiaries, or any of its
or their respective officers, directors, employees and agents, in addition to any other remedy
provided herein or in the Transaction Documents, a Buyer shall have the right to make a public
disclosure, in the form of a press release, public advertisement or otherwise, of such material,
nonpublic information without the prior approval by the Company, its Subsidiaries, or any of its or
their respective officers, directors, employees or agents. No Buyer shall have any liability to
the Company, its Subsidiaries, or any of its or their respective officers, directors, employees,
shareholders or agents for any such disclosure. Subject to the foregoing, neither the Company nor
any Buyer shall issue any press releases or any other public statements with respect to the
transactions contemplated hereby; provided, that the Company shall be entitled, without the
prior approval of any Buyer, to make any press release or other public disclosure with respect to
such transactions (i) in substantial conformity with the Initial 6-K Filing and Material Change
Report and contemporaneously therewith and (ii) as is required by applicable law and regulations
(provided that in the case of clause (i) each Buyer shall be consulted by the Company in connection
with any such press release or other public disclosure prior to its release). Without the prior
written consent of any applicable Buyer, the Company shall not disclose the name of any Buyer in
any filing, announcement, release or otherwise.

(j) Restriction on Redemption and Cash Dividends. So long as any Notes or Warrants
are outstanding or the Buyers shall have the right to purchase any Additional Notes, the Company
shall not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on,
the Common Stock without the prior express written consent of the holders of Notes representing not
less than a majority of the aggregate principal amount of the then outstanding Notes.

(k) Dilutive Issuances. For so long as any Notes or Warrants remain outstanding or
the Buyer shall have the right to purchase any Additional Notes, the Company shall not, in any
manner, enter into or effect any Dilutive Issuance (as defined in the Notes) if the effect of such
Dilutive Issuance is to cause the Company to be required to issue upon conversion of any Note or
exercise of any Warrant any shares of Common Stock in excess of that number of shares of Common
Stock which the Company may issue upon conversion of the Notes and exercise of the Warrants without
breaching the Company’s obligations under the rules or regulations of the Principal Market and
applicable Canadian Securities Laws.

(l) Corporate Existence. So long as any Buyer beneficially owns any Notes or Warrants
or the Buyer shall have the right to purchase any Additional Notes, the Company shall not be party
to any Fundamental Transaction (as defined in the Notes) unless the Company is in compliance with
the applicable provisions governing Fundamental Transactions set forth in the Notes and the
Warrants.

(m) Reservation of Shares. The Company shall take all action necessary to at all
times have authorized, and reserved for the purpose of issuance, after the Closing Date, at least
the requisite number of Interest Shares issuable pursuant to the terms of the Notes, shares of
Common Stock issuable upon conversion of all of the Notes (including the Additional Notes) and
shares of Common Stock issuable upon exercise of the Warrants.

(n) Conduct of Business. The business of the Company and its Subsidiaries shall not
be conducted in violation of any law, ordinance or regulation of any governmental entity, except
where such violations would not result, either individually or in the aggregate, in a Material
Adverse Effect.

(o) Additional Issuances of Securities.

(i) For purposes of this Section 4(o), the following definitions shall apply.

(1) “Convertible Securities” means any stock or securities (other than Options)
convertible into or exercisable or exchangeable for shares of Common Stock.

(2) “Options” means any rights, warrants or options to subscribe for or purchase shares
of Common Stock or Convertible Securities.

(3) “Common Stock Equivalents” means, collectively, Options and Convertible Securities.

(ii) From the date hereof until the two year anniversary of the Closing Date, the Company will
not, directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or
announce any offer, sale, grant or any option to purchase or other disposition of) any of its or
its Subsidiaries’ equity or equity equivalent securities, including without limitation any debt,
preferred stock or other instrument or security that is, at any time during its life and under any
circumstances, convertible into or exchangeable or exercisable for shares of Common Stock or Common
Stock Equivalents (any such offer, sale, grant, disposition or announcement being referred to as a
"Subsequent Placement”) unless the Company shall have first complied with this Section 4(o)(ii).

(1) The Company shall deliver to each Buyer a written notice (the “Offer Notice”) of
any proposed or intended issuance or sale or exchange (the “Offer”) of the securities being
offered (the “Offered Securities”) in a Subsequent Placement, which Offer Notice shall (w)
identify and describe the Offered Securities, (x) attach a copy of a term sheet or otherwise
describe the price and other material terms upon which they are to be issued, sold or
exchanged, and the number or amount of the Offered Securities to be issued, sold or
exchanged, (y) identify the persons or entities (if known) to which or with which the
Offered Securities are to be offered, issued, sold or exchanged and (z) offer to issue and
sell to such Buyers a pro rata portion of 30% of the Offered Securities allocated among such
Buyers (a) based on such Buyer’s pro rata portion of the aggregate principal amount of Notes
purchased hereunder (the “Basic Amount”), and (b) with respect to each Buyer that elects to
purchase its Basic Amount, any additional portion of the Offered Securities attributable to
the Basic Amounts of other Buyers as such Buyer shall indicate it will purchase or acquire
should the other Buyers subscribe for less than their Basic Amounts (the “Undersubscription
Amount”).

(2) To accept an Offer, in whole or in part, such Buyer must deliver a written notice
to the Company prior to the end of the seventh (7th) Business Day after such
Buyer’s receipt of the Offer Notice (the “Offer Period”), setting forth the portion of such
Buyer’s Basic Amount that such Buyer elects to purchase and, if such Buyer shall elect to
purchase all of its Basic Amount, the Undersubscription Amount, if any, that such Buyer
elects to purchase (in either case, the “Notice of Acceptance”). If the Basic Amounts
subscribed for by all Buyers are less than the total of all of the Basic Amounts, then each
Buyer who has set forth an Undersubscription Amount in its Notice of Acceptance shall be
entitled to purchase, in addition to the Basic Amounts subscribed for, the Undersubscription
Amount it has subscribed for; provided, however, that if the
Undersubscription Amounts subscribed for exceed the difference between the total of all the
Basic Amounts and the Basic Amounts subscribed for (the “Available Undersubscription
Amount”), each Buyer who has subscribed for any Undersubscription Amount shall be entitled
to purchase only that portion of the Available Undersubscription Amount as the Basic Amount
of such Buyer bears to the total Basic Amounts of all Buyers that have subscribed for
Undersubscription Amounts, subject to rounding by the Company to the extent its deems
reasonably necessary.

(3) The Company shall have twenty (20) Business Days from the expiration of the Offer
Period above to offer, issue, sell or exchange all or any part of such Offered Securities as
to which a Notice of Acceptance has not been given by the Buyers (the “Refused Securities”),
but only to the offerees described in the Offer Notice (if so described therein) and only
upon terms and conditions (including, without limitation, unit prices and interest rates)
that are not more favorable to the acquiring person or persons or less favorable to the
Company than those set forth in the Offer Notice.

(4) In the event the Company shall propose to sell less than all the Refused Securities
(any such sale to be in the manner and on the terms specified in Section 4(o)(ii)(3) above),
then each Buyer may, at its sole option and in its sole discretion, reduce the number or
amount of the Offered Securities specified in its Notice of Acceptance to an amount that
shall be not less than the number or amount of the Offered Securities that such Buyer
elected to purchase pursuant to Section 4(o)(ii)(2) above multiplied by a fraction, (i) the
numerator of which shall be the number or amount of Offered Securities the Company actually
proposes to issue, sell or exchange (including Offered Securities to be issued or sold to
Buyers pursuant to Section 4(o)(ii)(3) above prior to such reduction) and (ii) the
denominator of which shall be the original amount of the Offered Securities. In the event
that any Buyer so elects to reduce the number or amount of Offered Securities specified in
its Notice of Acceptance, the Company may not issue, sell or exchange more than the reduced
number or amount of the Offered Securities unless and until such securities have again been
offered to the Buyers in accordance with Section 4(o)(ii)(1) above.

(5) Upon the closing of the issuance, sale or exchange of all or less than all of the
Refused Securities, the Buyers shall acquire from the Company, and the Company shall issue
to the Buyers, the number or amount of Offered Securities specified in the Notices of
Acceptance, as reduced pursuant to Section 4(o)(ii)(3) above if the Buyers have so elected,
upon the terms and conditions specified in the Offer. The purchase by the Buyers of any
Offered Securities is subject in all cases to the preparation, execution and delivery by the
Company and the Buyers of a purchase agreement relating to such Offered Securities
reasonably satisfactory in form and substance to the Buyers and their respective counsel.

(6) Any Offered Securities not acquired by the Buyers or other persons in accordance
with Section 4(o)(ii)(3) above may not be issued, sold or exchanged until they are again
offered to the Buyers under the procedures specified in this Agreement.

(iii) The restrictions contained in subsection (ii) of this Section 4(o) shall not apply in
connection with the issuance of any Excluded Securities (as defined in the Notes).

(p) Effect of Failure to Cause Conversion Shares, Warrant Shares and Interest Shares to be
Freely Tradeable on Principal Market. On or prior to (i) November 28, 2005, (the “TSX
Deadline”), the Company shall use commercially reasonable efforts cause the Initial Conversion
Shares, the Warrant Shares, any Interest Shares to be issued, and 4/5ths of the Additional
Conversion Shares, to be listed for trading on the Principal Market, and (ii) 120 days after the
Shareholder Approval Date, (the “Additional TSX Deadline”), the Company shall use commercially
reasonable efforts cause any other Additional Conversion Shares to be listed for trading on the
Principal Market, and in each case, for so long as the Buyers hold any Securities or shall have the
right to purchase any Additional Notes, the Company shall cause such Securities to remain listed
after the applicable deadline for trading on the Principal Market. If the Company shall fail to
cause such securities to be listed for trading by the TSX Deadline or the Additional TSX Deadline
(a “TSX Failure”) or such securities fail to remain listed for trading after the applicable
deadline for longer than 5 consecutive Business Days or 10 Business Days in any twelve month
period, (a “Maintenance Failure”), then, as partial relief for the damages to any holder by reason
of any such delay in or reduction of its ability to sell the underlying Shares of Common Stock
(which remedy shall not be exclusive of any other remedies available at law or in equity), the
Company shall pay to each holder of such securities an amount in cash equal to one percent (1.0%)
of the aggregate Purchase Price of such Buyer’s Notes relating to such securities on each of the
following dates: (i) on every thirtieth day after the day of a TSX Failure and thereafter (pro
rated for periods totaling less than thirty days) until such a TSX Failure is cured; and (ii) on
every thirtieth day after the initial day of a Maintenance Failure and thereafter (pro rated for
periods totaling less than thirty days) until such Maintenance Failure is cured; provided,
that if a TSX Failure or a Maintenance Failure has continued for 270 days or more, the amount the
Company shall pay shall be increased to two percent (2.0%) of the aggregate principal amount of the
Buyer’s Notes relating to such securities. The payments to which a holder shall be entitled
pursuant to this Section 4(p) are referred to herein as “TSX Delay Payments.” TSX Delay Payments
shall be paid on the earlier of (I) the last day of the calendar month during which any such TSX
Delay Payment is incurred and (II) the third Business Day after the event or failure giving rise to
a TSX Delay Payment is cured. In the event the Company fails to make any TSX Delay Payment in a
timely manner, such TSX Delay Payment shall bear interest at the rate of one percent (1.0%) per
month (prorated for partial months) until paid in full.

(q) Holding Period. For the purposes of Rule 144 and applicable Canadian Securities
Laws, the Company acknowledges that the holding period of the Conversion Shares and the Warrant
Shares may be tacked onto the holding period of the Notes and Warrants, as applicable, and the
Company agrees not to take a position contrary to this Section 4(q).

(r) Cash Collateral Account. (i) As of Closing the Company shall establish with a
bank acceptable to Portside Growth Opportunity Fund, as collateral agent (the “Collateral Agent”),
(the “Cash Collateral Bank”) a deposit account (together with all monies on deposit in such deposit
account and all certificates and instruments, if any, representing or evidencing such deposit
account, the “Cash Collateral Account”), and shall cause the Cash Collateral Bank to enter to an
account control agreement with the Collateral Agent, on terms reasonably acceptable to the
Collateral Agent. Upon the request of the Collateral Agent, the Company shall also execute and
deliver such other customary agreements and instruments necessary to grant the Buyers a first
priority perfected security interest and hypothec in the Cash Collateral Account to secure the
Notes. The Company agrees that it shall not permit the Cash Collateral Account to be subject to
any lien, pledge, charge, hypothec, security interest or other encumbrance other than as provided
in the immediately preceding sentence.

(ii) The funds in the Cash Collateral Account shall be distributed as set forth below:

(1) If the Company raises after the Closing Date more than $4.0 million but less than
or equal to $7.0 million in aggregate net proceeds in a Subsequent Placement, then on the
third Business Day after receiving notice from the Company of such event, the Collateral
Agent shall deliver written instructions to the Cash Collateral Bank directing the release
to the Company from the Cash Collateral Account of any funds in excess of $1.0 million;

(2) If the Company raises after the Closing Date more than $7.0 million in aggregate
net proceeds in a Subsequent Placement, then on the third Business Day after receiving
notice from the Company of such event, the Collateral Agent shall deliver written
instructions to the Cash Collateral Bank directing the release of the balance of any amount
remaining in the Cash Collateral Account to the Company;

(3) If at any time or from time to time the aggregate principal amount of the Notes
falls below the amount in the Cash Collateral Account (whether by conversion, redemption,
amortization or otherwise), then on the third Business Day after receiving notice from the
Company of such event, the Cash Collateral Agent shall deliver written instructions to the
Cash Collateral Bank directing the release to the Company, from the Cash Collateral Account,
of an amount equal to $1 for each $1 that the aggregate principal amount of the Notes is
below the amount in the Cash Collateral Account; and

(4) If any balance remains in the Cash Collateral Account on the Maturity Date, then on
the third Business Day after receiving notice from the Company of such event, the Collateral
Agent shall deliver written instructions to the Cash Collateral Bank directing it to release
to the holders of the Notes (allocated pro rata among the holders based on the principal
amount of the Notes held by each holder on the Maturity Date) the balance of any such amount
remaining in the Cash Collateral Account.

(s) Shareholder Approval. The Company shall hold a special or annual meeting of
shareholders of the Company (the “Shareholder Meeting”), which shall be promptly called and held
not later than May 31, 2006 (the “Shareholder Meeting Deadline”), soliciting each such
shareholder’s affirmative vote for approval of resolutions providing for the Company’s issuance of
all of the Second Additional Notes and any Securities not currently authorized to be issued by the
Principal Market (such affirmative approval being referred to herein as the “Shareholder Approval”,
and the date of such approval, the “Shareholder Approval Date”), and the Company shall use its
reasonable best efforts to solicit its shareholders’ approval of such resolutions and to cause the
Board of Directors of the Company to recommend to the shareholders that they approve such
resolutions. The Company shall be obligated to seek to obtain the Shareholder Approval by the
Shareholder Meeting Deadline. If, despite the Company’s reasonable best efforts the Shareholder
Approval is not obtained on or prior to the Shareholder Meeting Deadline, the Company shall cause
two (2) additional Shareholder Meetings to be held every six months thereafter until such
Shareholder Approval is obtained.

(t) Future Guaranties. The Company shall not acquire or create any new subsidiaries
or transfer any assets of any kind or nature to either of the Company’s subsidiaries as of the
Closing Date (the “Existing Subsidiaries”) or to any new subsidiary unless, concurrently with any
such transactions, the Company has caused such Existing Subsidiary or such new subsidiary to become
a party to the Hypothec Agreement and to execute a Guarantee in the form attached hereto as
Exhibit I.

(u) Account Control Agreement. (i) Within ten (10) Business Days after the Closing
Date, the Company shall use commercially reasonable efforts to deliver to the Buyers an Account
Control Agreement, in form and substance reasonably satisfactory to the Senior Agent, for each bank
account of the Company, duly authorized and executed by the Company and the applicable bank.

(ii) Following the Closing Date, and so long as any Notes are outstanding, neither the Company
nor any of its Subsidiaries shall open any account with any bank or other financial entity without
delivering to the Buyers an Account Control Agreement, in form and substance substantially similar
to the Account Control Agreement referenced in clause (i) above, for each such account of the
Company or such Subsidiary, duly authorized and executed by the Company or such Subsidiary and the
applicable bank or other financial entity.

(iii) Notwithstanding the terms of any such Account Control Agreement, the Senior Agent shall
not provide instructions to the applicable bank directing the disposition of the funds in the
subject account or any other dealings with such account unless an Event of Default (as defined in
the Notes) has occurred and is continuing.

5. REGISTER; TRANSFER AGENT INSTRUCTIONS.

(a) Register. The Company shall maintain at its principal executive offices (or such
other office or agency of the Company as it may designate by notice to each holder of Securities),
a register for the Notes and the Warrants in which the Company shall record the name and address of
the Person in whose name the Notes and the Warrants have been issued (including the name and
address of each transferee), the principal amount of Notes held by such Person, the number of
Interest Shares issuable pursuant to the terms of the Notes, Conversion Shares issuable upon
conversion of the Notes and Warrant Shares issuable upon exercise of the Warrants held by such
Person. The Company shall keep the register open and available at all times during business hours
for inspection of any Buyer or its legal representatives.

(b) Transfer Agent Instructions. The Company shall issue irrevocable instructions to
its transfer agent, and any subsequent transfer agent, to issue certificates or credit shares to
the applicable balance accounts at The Depository Trust Company (“DTC”), registered in the name of
each Buyer or its respective nominee(s), for the Conversion Shares, the Interest Shares, if any,
and the Warrant Shares issued at the Closing or upon conversion of the Notes or exercise of the
Warrants in such amounts as specified from time to time by each Buyer to the Company upon
conversion of the Notes or exercise of the Warrants in the form of Exhibit D attached
hereto (the “Irrevocable Transfer Agent Instructions”). The Company warrants that no instruction
other than the Irrevocable Transfer Agent Instructions referred to in this Section 5(b), and stop
transfer instructions to give effect to Section 2(g) hereof, will be given by the Company to its
transfer agent, and that the Securities shall otherwise be freely transferable on the books and
records of the Company as and to the extent provided in this Agreement and the other Transaction
Documents. If a Buyer effects a sale, assignment or transfer of the Securities in accordance with
Section 2(f), the Company shall permit the transfer and shall promptly instruct its transfer agent
to issue one or more certificates or credit shares to the applicable balance accounts at DTC in
such name and in such denominations as specified by such Buyer to effect such sale, transfer or
assignment. In the event that such sale, assignment or transfer involves Conversion Shares,
Interest Shares or Warrant Shares sold, assigned or transferred pursuant to an effective
registration statement or pursuant to Rule 144, the transfer agent shall issue such Securities to
the Buyer, assignee or transferee, as the case may be, without any restrictive legend. The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to a
Buyer. Accordingly, the Company acknowledges that the remedy at law for a breach of its
obligations under this Section 5(b) will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Section 5(b), that a Buyer shall be
entitled, in addition to all other available remedies, to an order and/or injunction restraining
any breach and requiring immediate issuance and transfer, without the necessity of showing economic
loss and without any bond or other security being required.

6. CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

(a) Initial Closing Date. The obligation of the Company hereunder to issue and sell
the Notes and the related Warrants to each Buyer at the Initial Closing is subject to the
satisfaction, at or before the Initial Closing Date, of each of the following conditions, provided
that these conditions are for the Company’s sole benefit and may be waived by the Company at any
time in its sole discretion by providing each Buyer with prior written notice thereof:

(i) Such Buyer shall have executed each of the Transaction Documents to which it is a party
and delivered the same to the Company.

(ii) Such Buyer and each other Buyer shall have delivered to the Company the Purchase Price
(less, in the case of Portside Growth & Opportunity Fund, the amounts withheld pursuant to Section
4(g)) for the Notes and the related Warrants being purchased by such Buyer at the Closing by wire
transfer of immediately available funds pursuant to the wire instructions provided by the Company.

(iii) The representations and warranties of such Buyer shall be true and correct in all
material respects as of the date when made and as of the Initial Closing Date as though made at
that time (except for representations and warranties that speak as of a specific date), and such
Buyer shall have performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by this Agreement to be performed, satisfied or complied with by
such Buyer at or prior to the Initial Closing Date.

(b) Additional Closing Date. The obligation of the Company hereunder to issue and
sell the Notes to each Buyer at each Additional Closing is subject to the satisfaction, at or
before such Additional Closing Date, of each of the following conditions, provided that these
conditions are for the Company’s sole benefit and may be waived by the Company at any time in its
sole discretion by providing each Buyer with prior written notice thereof:

(i) Such Buyer and each other Buyer shall have delivered to the Company the Purchase Price for
the Additional Notes being purchased by such Buyer at such Closing by wire transfer of immediately
available funds pursuant to the wire instructions provided by the Company.

(ii) The representations and warranties of such Buyer shall be true and correct in all
material respects as of the date when made and as of Additional Closing Date as though made at that
time (except for representations and warranties that speak as of a specific date), and such Buyer
shall have performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by this Agreement to be performed, satisfied or complied with by
such Buyer at or prior to such Closing Date.

7. CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE.

(a) Initial Closing Date. The obligation of each Buyer hereunder to purchase the
Notes and the related Warrants at the Initial Closing is subject to the satisfaction, at or before
the Initial Closing Date, of each of the following conditions, provided that these conditions are
for each Buyer’s sole benefit and may be waived by such Buyer at any time in its sole discretion by
providing the Company with prior written notice thereof:

(i) The Company and, to the extent it is a party thereto, each of its Existing Subsidiaries,
shall have duly executed and delivered to such Buyer: (A) the Initial Notes (in such principal
amounts as such Buyer shall request) being purchased by such Buyer at the Initial Closing pursuant
to this Agreement, (B) the Warrants (in such amounts as such Buyer shall request) being purchased
by such Buyer at the Initial Closing pursuant to this Agreement; and (C) each of the other
Transaction Documents.

(ii) Such Buyer shall have received the opinion of Osler, Hoskin & Harcourt LLP, the Company’s
outside counsel, dated as of the Initial Closing Date, in substantially the form of Exhibit
E attached hereto.

(iii) The Company shall have delivered to such Buyer a copy of the Irrevocable Transfer Agent
Instructions, in the form of Exhibit D attached hereto, which instructions shall have been
delivered to and acknowledged in writing by the Company’s transfer agent.

(iv) The Company shall have delivered to such Buyer a certificate evidencing the formation and
good standing of the Company in such entity’s jurisdiction of formation issued by the Secretary of
State (or comparable office) of such jurisdiction, as of a date within 10 days of the Initial
Closing Date.

(v) The Company shall have delivered to such Buyer a certified copy of the Articles of
Incorporation as certified by The Director, Canada Business Corporations Act, Industry Canada,
within ten (10) days of the Initial Closing Date.

(vi) The Company shall have delivered to such Buyer a certificate, executed by the Secretary
of the Company and dated as of the Initial Closing Date, as to (i) the resolutions consistent with
Section 3(b) as adopted by the Company’s Board of Directors in a form reasonably acceptable to such
Buyer, (ii) the Certificate of Incorporation and (iii) the Bylaws, each as in effect at the Initial
Closing, in the form attached hereto as Exhibit F.

(vii) The representations and warranties of the Company shall be true and correct in all
material respects (except for those representations and warranties that are qualified by
materiality or Material Adverse Effect, which shall be true and correct in all respects) as of the
date when made and as of the Initial Closing Date as though made at that time (except for
representations and warranties that speak as of a specific date) and the Company shall have
performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by the Transaction Documents to be performed, satisfied or complied with by the
Company at or prior to the Initial Closing Date. Such Buyer shall have received a certificate,
executed by the Chief Executive Officer of the Company, dated as of the Initial Closing Date, to
the foregoing effect and as to such other matters as may be reasonably requested by such Buyer in
the form attached hereto as Exhibit G.

(viii) The Company shall have delivered to such Buyer a letter from the Company’s transfer
agent certifying the number of shares of Common Stock outstanding as of a date within five days of
the Initial Closing Date.

(ix) The Common Stock (i) shall be or listed on the Principal Market and (ii) shall not have
been suspended, as of the Initial Closing Date, by the SEC, the CSA or the Principal Market from
trading on the Principal Market nor shall suspension by the SEC, the CSA or the Principal Market
have been threatened, as of the Initial Closing Date, either (A) in writing by the SEC, the CSA or
the Principal Market or (B) by falling below the minimum listing maintenance requirements of the
Principal Market.

(x) The Company shall have obtained all governmental, regulatory or third party consents and
approvals, if any, necessary for the sale of the Securities.

(xi) There shall be no Indebtedness of the Company other than Indebtedness which is
subordinate to the Notes.

(xii) A pay-off letter in form and substance satisfactory to the Senior Agent from Canadian
Imperial Bank of Commerce.

(xiii) The approval of the Principal Market for the issuance of the Securities contemplated
hereby and conditional listing of the Conversion Shares, Warrant Shares and Interest Shares shall
have been obtained.

(xiv) The approval of the board of directors of the Company for the issuance of the Securities
contemplated hereby shall have been obtained.

(xv) The Company shall have delivered to such Buyer such other documents relating to the
transactions contemplated by this Agreement as such Buyer or its counsel may reasonably request.

(b) Additional Closing Date. The obligation of each Buyer hereunder to purchase the
Notes and the related Warrants at the each Additional Closing is subject to the satisfaction, at or
before such Additional Closing Date, of each of the following conditions, provided that these
conditions are for each Buyer’s sole benefit and may be waived by such Buyer at any time in its
sole discretion by providing the Company with prior written notice thereof:

(i) The Company and, to the extent it is a party thereto, each of its Existing Subsidiaries,
shall have duly executed and delivered to such Buyer the Additional Notes (in such principal
amounts as such Buyer shall request) being purchased by such Buyer at such Additional Closing
pursuant to this Agreement.

(ii) Such Buyer shall have received the opinion of Osler, Hoskin & Harcourt LLP, the Company’s
outside counsel, dated as of the each Additional Closing Date, in substantially the form of
Exhibit E attached hereto.

(iii) The Company shall have delivered to such Buyer a copy of the Irrevocable Transfer Agent
Instructions, in the form of Exhibit D attached hereto, which instructions shall have been
delivered to and acknowledged in writing by the Company’s transfer agent.

(iv) The Company shall have delivered to such Buyer a certificate evidencing the formation and
good standing of the Company in such entity’s jurisdiction of formation issued by the Secretary of
State (or comparable office) of such jurisdiction, as of a date within 10 days of such Additional
Closing Date.

(v) The Company shall have delivered to such Buyer a certified copy of the Articles of
Incorporation as certified by The Director, Canada Business Corporations Act, Industry Canada,
within ten (10) days of such Additional Closing Date.

(vi) The Company shall have delivered to such Buyer a certificate, executed by the Secretary
of the Company and dated as of such Additional Closing Date, as to (A) the Certificate of
Incorporation and (B) the Bylaws, each as in effect at such Additional Closing, in the form
attached hereto as Exhibit F.

(vii) The representations and warranties of the Company shall be true and correct in all
material respects (except for those representations and warranties that are qualified by
materiality or Material Adverse Effect, which shall be true and correct in all respects) as of the
date when made and as of such Additional Closing Date as though made at that time (except for
representations and warranties that speak as of a specific date) and the Company shall have
performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by the Transaction Documents to be performed, satisfied or complied with by the
Company at or prior to such Additional Closing Date. Such Buyer shall have received a certificate,
executed by the Chief Executive Officer of the Company, dated as of such Additional Closing Date,
to the foregoing effect and as to such other matters as may be reasonably requested by such Buyer
in the form attached hereto as Exhibit G.

(viii) The Company shall have delivered to such Buyer a letter from the Company’s transfer
agent certifying the number of shares of Common Stock outstanding as of a date within five days of
such Additional Closing Date.

(ix) The Common Stock (i) shall be listed on the Principal Market and (ii) shall not have been
suspended, as of such Additional Closing Date, by the SEC, the CSA or the Principal Market from
trading on the Principal Market nor shall suspension by the SEC, he CSA or the Principal Market
have been threatened, as of such Additional Closing Date, either (A) in writing by the SEC, the CSA
or the Principal Market or (B) by falling below the minimum listing maintenance requirements of the
Principal Market.

(x) The Company shall have obtained all governmental, regulatory or third party consents and
approvals, if any, necessary for the sale of the applicable Additional Notes.

(xi) No Event of Default (as defined in the Notes) shall have occurred and be continuing.

(xii) The approval of the Principal Market for the issuance of the Securities issuable on such
Additional Closing Date and the conditional listing of the Conversion Shares, Warrant Shares and
Interest Shares on the Principal Market shall have remained continuously in effect from the time of
the Initial Closing Date.

(xiii) The Company shall have duly executed and delivered to such Buyer an additional Hypothec
Agreement with respect to the Additional Notes, substantially in the form attached hereto as
Exhibit H, but which shall be limited in amount to CDN$6 million.

(xiv) The Company shall have delivered to such Buyer such other documents relating to the
transactions contemplated by this Agreement as such Buyer or its counsel may reasonably request.

8. SENIOR AGENT

Each of the Buyers hereby irrevocably designates and appoints Portside Growth & Opportunity
Fund as the Senior Agent under the Security Documents and, without prejudice to the foregoing, each
Buyer designates and appoints the Senior Agent as the person holding power of attorney (fondé de
pouvoir) of the Buyers as contemplated under Article 2692 of the Civil Code of Quebec, to enter
into, to take and to hold on each of their behalfs, and for their benefit, the Hypothec Agreement
and any other of the Security Documents and to exercise such powers and duties which are conferred
thereupon under such deeds or documents.

9. TERMINATION.

Subject to Section 1(a)(i) above, in the event that the Closing shall not have occurred with
respect to a Buyer on or before five (5) Business Days from the date hereof due to the Company’s or
such Buyer’s failure to satisfy the conditions set forth in Sections 6 and 7 above (and the
nonbreaching party’s failure to waive such unsatisfied condition(s)), the nonbreaching party shall
have the option to terminate this Agreement with respect to such breaching party at the close of
business on such date without liability of any party to any other party; provided, however, this if
this Agreement is terminated by the Company pursuant to this Section 8, the Company shall remain
obligated to reimburse the non-breaching Buyers for the expenses described in Section 4(g) above.

10. MISCELLANEOUS.

(a) Governing Law; Jurisdiction; Jury Trial. All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by the
internal laws of the State of New York, without giving effect to any choice of law or conflict of
law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof
to such party at the address for such notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. The Company
hereby appoints Osler, Hoskin & Harcourt LLP, with offices at 1221 Avenue of the Americas, 26th
floor, New York, N.Y., 10020 – 1089, as its agent for service of process in New York. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO
REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR
ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

(b) Judgment Currency.

(i) If for the purpose of obtaining or enforcing judgment against the Company in any court in
any jurisdiction it becomes necessary to convert into any other currency (such other currency being
hereinafter in this Section 10(b) referred to as the “Judgment Currency”) an amount due in US
dollars under this Agreement, the conversion shall be made at the Exchange Rate prevailing on the
Business Day immediately preceding:

(1) the date of actual payment of the amount due, in the case of any proceeding in the
courts of New York or in the courts of any other jurisdiction that will give effect to such
conversion being made on such date: or

(2) the date on which the foreign court determines, in the case of any proceeding in
the courts of any other jurisdiction (the date as of which such conversion is made pursuant
to this Section 10(b)(i)(2) being hereinafter referred to as the “Judgment Conversion
Date”).

(ii) If in the case of any proceeding in the court of any jurisdiction referred to in Section
10(b)(i)(2) above, there is a change in the Exchange Rate prevailing between the Judgment
Conversion Date and the date of actual payment of the amount due, the applicable party shall pay
such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency,
when converted at the Exchange Rate prevailing on the date of payment, will produce the amount of
US dollars which could have been purchased with the amount of Judgment Currency stipulated in the
judgment or judicial order at the Exchange Rate prevailing on the Judgment Conversion Date.

(iii) Any amount due from the Company under this provision shall be due as a separate debt and
shall not be affected by judgment being obtained for any other amounts due under or in respect of
this Agreement.

(c) Counterparts. This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party;
provided that a facsimile signature shall be considered due execution and shall be binding upon the
signatory thereto with the same force and effect as if the signature were an original, not a
facsimile signature.

(d) Headings. The headings of this Agreement are for convenience of reference and
shall not form part of, or affect the interpretation of, this Agreement.

(e) Severability. If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the
validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity
or enforceability of any provision of this Agreement in any other jurisdiction.

(f) Entire Agreement; Amendments. This Agreement supersedes all other prior oral or
written agreements between the Buyers, the Company, their affiliates and Persons acting on their
behalf with respect to the matters discussed herein, and this Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect to the matters
covered herein and therein and, except as specifically set forth herein or therein, neither the
Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to
such matters. No provision of this Agreement may be amended other than by an instrument in writing
signed by the Company and the holders of at least a majority of the aggregate principal amount of
Notes issued and issuable hereunder, and any amendment to this Agreement made in conformity with
the provisions of this Section 9(e) shall be binding on all Buyers and holders of Securities, as
applicable. No provision hereof may be waived other than by an instrument in writing signed by the
party against whom enforcement is sought. No such amendment shall be effective to the extent that
it applies to less than all of the holders of the applicable Securities then outstanding. No
consideration shall be offered or paid to any Person to amend or consent to a waiver or
modification of any provision of any of the Transaction Documents unless the same consideration
also is offered to all of the parties to the Transaction Documents, holders of Notes or holders of
the Warrants, as the case may be. The Company has not, directly or indirectly, made any agreements
with any Buyers relating to the terms or conditions of the transactions contemplated by the
Transaction Documents except as set forth in the Transaction Documents.

(g) Notices. Any notices, consents, waivers or other communications required or
permitted to be given under the terms of this Agreement must be in writing and will be deemed to
have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by
facsimile (provided confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one Business Day after deposit with an overnight
courier service, in each case properly addressed to the party to receive the same. The addresses
and facsimile numbers for such communications shall be:

	 	 	 
	If to the Company:

	 	

	 
	 	 
	ART Advanced Research Technologies, Inc.

	 
	 	 
	2300 Alfred-Nobel Blvd.

	 	

	 
	 	 
	Saint Laurent, Québec H4S 2A4 Canada

	 
	 	 
	Telephone:

Facsimile:

Attention:

	 	(514) 832-0077

(514) 832-0778

Sébastien Gignac, Secretary and General Counsel

Copy to:

	 	 	 
	Osler, Hoskin & Harcourt LLP

	 	

	 
	 	 
	1000 de La Gauchetiére Street West

	 
	 	 
	Suite 2100

Montréal Québec

H3B 4W5 Canada

Telephone:

Facsimile:

Attention:

	 	

(514) 904-8120

(514) 904-8101

Robert Yalden, Esq.

	 	 	 	 	 
	If to the Transfer Agent:

	National Bank Trust
1100 University Avenue
9th Floor
Montreal, Quebec
H3B 2G7
Telephone:
	 	 	(514) 871-7408	 
	Facsimile:
	 	 	(514)871-7434	 

Attention: Manager, Share Ownership Management

If to a Buyer, to its address and facsimile number set forth on the Schedule of Buyers, with copies
to such Buyer’s representatives as set forth on the Schedule of Buyers,

	 	 	 	 	 
	with a copy (for informational purposes only) to:

	Schulte Roth & Zabel LLP
919 Third Avenue
New York, New York 10022
Telephone:
	 	 	(212) 756-2000	 
	Facsimile:
	 	 	(212) 593-5955	 
	Attention:
	 	Eleazer N. Klein, Esq.

or to such other address and/or facsimile number and/or to the attention of such other Person as
the recipient party has specified by written notice given to each other party five (5) days prior
to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of
such notice, consent, waiver or other communication, (B) mechanically or electronically generated
by the sender’s facsimile machine containing the time, date, recipient facsimile number and an
image of the first page of such transmission or (C) provided by an overnight courier service shall
be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight
courier service in accordance with clause (i), (ii) or (iii) above, respectively.

(h) Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective successors and assigns, including any purchasers of the
Notes or the Warrants. The Company shall not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the holders of at least a majority of the aggregate
principal amount of Notes issued and issuable hereunder, including by way of a Fundamental
Transaction (unless the Company is in compliance with the applicable provisions governing
Fundamental Transactions set forth in the Notes and the Warrants). A Buyer may assign some or all
of its rights hereunder without the consent of the Company in connection with a transfer by such
Buyer of any of the Securities, in which event such assignee shall be deemed to be a Buyer
hereunder with respect to such assigned rights.

(i) No Third Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective permitted successors and assigns, and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

(j) Survival. Unless this Agreement is terminated under Section 8, the
representations and warranties of the Company and the Buyers contained in Sections 2 and 3 and the
agreements and covenants set forth in Sections 4, 5 and 9 shall survive the Closing. Each Buyer
shall be responsible only for its own representations, warranties, agreements and covenants
hereunder.

(k) Currency. Unless otherwise indicated, all dollar amounts referred to in this
Agreement are in United States Dollars. All amounts owing under this Agreement or any Transaction
Document shall be paid in US dollars. All amounts denominated in other currencies shall be
converted in the US dollar equivalent amount in accordance with the Exchange Rate on the date of
calculation. “Exchange Rate” means, in relation to any amount of currency to be converted into US
dollars pursuant to this Agreement, the US dollar exchange rate as published in the Wall Street
Journal on the relevant date of calculation.

(l) Further Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as any other party may reasonably request in
order to carry out the intent and accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby.

(m) Indemnification. In consideration of each Buyer’s execution and delivery of the
Transaction Documents and acquiring the Securities thereunder and in addition to all of the
Company’s other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless each Buyer and each other holder of the Securities and all of their
shareholders, partners, members, officers, directors, employees and direct or indirect investors
and any of the foregoing Persons’ agents or other representatives (including, without limitation,
those retained in connection with the transactions contemplated by this Agreement) (collectively,
the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses,
costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective
of whether any such Indemnitee is a party to the action for which indemnification hereunder is
sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified
Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any
material inaccuracy in any representation or warranty made by the Company in the Transaction
Documents or any inaccuracy in any representation or warranty in the Transaction Documents that is
qualified by materiality or Material Adverse Effect, (b) any breach of any covenant, agreement or
obligation of the Company contained in the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby or (c) any cause of action, suit or claim
brought or made against such Indemnitee by a third party (including for these purposes a derivative
action brought on behalf of the Company) and arising out of or resulting from (i) the execution,
delivery, performance or enforcement of the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby, (ii) any transaction financed or to be
financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the
Securities or (iii) the status of such Buyer or holder of the Securities as an investor in the
Company pursuant to the transactions contemplated by the Transaction Documents; provided,
that indemnification pursuant to this clause (iii) shall not be available to the extent arising
primarily from (i) such Buyer’s fraud, gross negligence or willful misconduct or (ii) a material
breach of any representation or warranty given by such Buyer. To the extent that the foregoing
undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum
contribution to the payment and satisfaction of each of the Indemnified Liabilities that is
permissible under applicable law.

(n) No Strict Construction. The language used in this Agreement will be deemed to be
the language chosen by the parties to express their mutual intent, and no rules of strict
construction will be applied against any party.

(o) Remedies. Each Buyer and each holder of the Securities shall have all rights and
remedies set forth in the Transaction Documents and all rights and remedies which such holders have
been granted at any time under any other agreement or contract and all of the rights which such
holders have under any law. Any Person having any rights under any provision of this Agreement
shall be entitled to enforce such rights specifically (without posting a bond or other security),
to recover damages by reason of any breach of any provision of this Agreement and to exercise all
other rights granted by law. Furthermore, the Company recognizes that in the event that it fails
to perform, observe, or discharge any or all of its obligations under the Transaction Documents,
any remedy at law may prove to be inadequate relief to the Buyers. The Company therefore agrees
that the Buyers shall be entitled to seek temporary and permanent injunctive relief in any such
case without the necessity of proving actual damages and without posting a bond or other security.

(p) Rescission and Withdrawal Right. Notwithstanding anything to the contrary
contained in (and without limiting any similar provisions of) the Transaction Documents, whenever
any Buyer exercises a right, election, demand or option under a Transaction Document and the
Company does not timely perform its related obligations within the periods therein provided, then
such Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to
the Company, any relevant notice, demand or election in whole or in part without prejudice to its
future actions and rights.

(q) Payment Set Aside. To the extent that the Company makes a payment or payments to
the Buyers hereunder or pursuant to any of the other Transaction Documents or the Buyers enforce or
exercise their rights hereunder or thereunder, and such payment or payments or the proceeds of such
enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or
otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, United States or Canadian federal, state or
provincial law, foreign law, common law or equitable cause of action), then to the extent of any
such restoration the obligation or part thereof originally intended to be satisfied shall be
revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred.

(r) Independent Nature of Buyers’ Obligations and Rights. The obligations of each
Buyer under any Transaction Document are several and not joint with the obligations of any other
Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any
other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction
Document, and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to
constitute the Buyers as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Buyers are in any way acting in concert or as a group with
respect to such obligations or the transactions contemplated by the Transaction Documents and the
Company acknowledges that the Buyers are not acting in concert or as a group with respect to such
obligations or the transactions contemplated by the Transaction Documents. Each Buyer confirms
that it has independently participated in the negotiation of the transaction contemplated hereby
with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently
protect and enforce its rights, including, without limitation, the rights arising out of this
Agreement or out of any other Transaction Documents, and it shall not be necessary for any other
Buyer to be joined as an additional party in any proceeding for such purpose.

[Signature Page Follows]

1

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to
this Securities Purchase Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	COMPANY:

	 

	ART ADVANCED RESEARCH TECHNOLOGIES, INC.

	 

	 

	 
	By:

	 

	Name:

	Title:

	 

2

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to
this Securities Purchase Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	BUYERS:

	 

	PORTSIDE GROWTH & OPPORTUNITY FUND

	 

	 

	 
	By:

	 

	Name:

	Title:

	 

3

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to
this Securities Purchase Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	BUYERS:

	 

	JGB CAPITAL L.P.

	 

	 

	 
	By:

	 

	Name:

	Title:

4

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature
page to this Securities Purchase Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	BUYERS:

	 

	SMITHFIELD FIDUCIARY LLC

	 

	 

	 
	By:

	 

	Name:

	Title:

5

IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature
page to this Securities Purchase Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	BUYERS:

	 

	LANGLEY PARTNERS, L.P.

	 

	 

	 
	By:

	 

	Name:

	Title:

6

SCHEDULE OF BUYERS

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(1)	 	(2)	 	(3)	 	(4)	 	(5)	 	(6)	 	(7)	 	(8)	 	(9)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Maximum Aggregate	 	Maximum Aggregate	 	 	 	 	 	 
	 	 	 	 	 	 	Aggregate Principal	 	 	 	 	 	 	 	 	 	Principal Amount of	 	Principal Amount of	 	 	 	 	 	 
	 	 	Address and	 	Amount of Initial	 	Number of A	 	Number of B	 	First Additional	 	Second Additional	 	 	 	 	 	Legal Representative's Address
	Buyer	 	Facsimile Number	 	Notes	 	Warrant Shares	 	Warrant Shares	 	Notes	 	Notes	 	Purchase Price	 	and Facsimile Number
	 
	 	c/o Ramius Capital Group, L.L.C.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	666 Third Avenue, 26th Floor	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	New York, New York  10017
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Schulte Roth & Zabel LLP

	 
	 	Attention:  Jeffrey Smith
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	919 Third Avenue
	 
	 	Michael Neidell
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	New York, New York  10022

	 
	 	Facsimile:  (212) 845-7999
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Attention:  Eleazer Klein, Esq.

	Portside Growth &
	 	Telephone: (212) 845-7955
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Facsimile: (212) 593-5955

	Opportunity Fund
	 	Residence:  Cayman Islands
	 	$	2,500,000	 	 	 	555,069	 	 	 	61,675	 	 	$	1,000,000.00	 	 	$	250,000.00	 	 	$	2,500,000	 	 	Telephone:  (212) 756-2376

	 
	 	660 Madison Avenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	21st Floor	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	New York, NY 10021
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Attention:  Brett Cohen
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Everett Alexander
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Facsimile:  (212) 253-4093
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Telephone: (212) 355-5771
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	JGB Capital L.P.
	 	E-mail: bcohen@jgbcap.com	 		1,000,000		 		222,028		 	 	24,670	 	 	 	400,000.00	 	 	 	100,000.00	 	 		1,000,000		 		N/A	
	 
	 	c/o Highbridge Capital Management, LLC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	9 West 57th Street	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	27th Floor	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	New York, NY 10019
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Attention:  Ari J. Storch
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Adam J. Chill
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Facsimile:  (212) 751-0755
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Smithfield Fiduciary
	 	Telephone: (212) 287-4720
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	LLC
	 	Residence:  Cayman Islands
	 		750,000		 		166,521		 	 	18,502	 	 	 	300,000.00	 	 	 	75,000.00	 	 		750,000		 		N/A	
	 
	 	c/o Langley Capital, LLP	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	535 Madison Avenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	7th Floor	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	New York, NY 10022
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Attention: Jeffery Thorp
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Facsimile: (212) 850-7589
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Telephone: (212) 850-7528
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Email: JeffreyThorp@lcap.com
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Residence: New York
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Langley Partners, L.P.
	 	State of Incorporation: Delaware
	 		750,000		 		166,521		 	 	18,502	 	 	 	300,000.00	 	 	 	75,000.00	 	 		750,000		 		N/A	
	Total
	 	 	 	 	 	$	5,000,000		 		1,110,139		 		123,349		 	$	2,000,000		 	$	500,000		 	$	5,000,000		 	 	 	 

7

EXHIBITS

	 	 	 
	Exhibit A

Exhibit B

Exhibit C

Exhibit D

Exhibit E

Exhibit F

Exhibit G

Exhibit H

Exhibit I

	 	Form of Notes

Form of A Warrants

Form of B Warrants

Irrevocable Transfer Agent Instructions

Form of Outside Company Counsel Opinion

Form of Secretary’s Certificate

Form of Officer’s Certificate

Form of Hypothec Agreement

Form of Guarantee
	 
	 	 

8Exhibit  EX-4.6

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE
SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED OR QUALIFIED UNDER THE
SECURITIES ACT OF 1933 (the “1933 ACT”), AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.

THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED WITHIN THE UNITED STATES
OR TO ANY U.S. PERSON (AS DEFINED IN RULE 902 OF THE 1933 ACT) (I) IN THE ABSENCE OF (A) AN
EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT, OR (B) AN OPINION OF
COUNSEL, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER
SAID ACT IN RELIANCE UPON RULE 144 OR RULE 144A UNDER SAID ACT OR ANOTHER AVAILABLE EXEMPTION.
NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES TOGETHER WITH OTHER
SECURITIES OF THE HOLDER.

UNLESS PERMITTED UNDER CANADIAN SECURITIES LAWS, THE HOLDER OF THIS WARRANT AND THE COMMON SHARES
ISSUABLE UPON EXERCISE OF THIS WARRANT SHALL NOT TRADE SUCH SECURITIES BEFORE NOVEMBER 28, 2005.

ART Advanced Research Technologies Inc.

Warrant To Purchase Common Shares

Warrant No.: A-1

Number of Common Shares: 555,069     

Date of Issuance: July 28, 2005 (“Issuance Date”)

ART Advanced Research Technologies Inc., a Canadian corporation (the “Company”), hereby
certifies that, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, PORTSIDE GROWTH AND OPPORTUNITY FUND, the registered holder hereof or its
permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase
from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this
Warrant to Purchase Common Shares (including any Warrants to Purchase Common Shares issued in
exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or after the
Issuance Date, but not after 11:59 p.m., New York Time, on the Expiration Date (as defined below),
FIVE HUNDRED AND FIFTY FIVE THOUSAND AND SIXTY NINE (555,069) fully paid non-assessable Common
Shares (as defined below) (the “Warrant Shares”). Except as otherwise defined herein, capitalized
terms in this Warrant shall have the meanings set forth in Section 15. This Warrant is one of the
Warrants to Purchase Common Shares (the “SPA Warrants”) issued pursuant to Section 1 of that
certain Securities Purchase Agreement, dated as of July 28, 2005 (the “Subscription Date”), by and
among the Company and the investors (the “Buyers”) referred to therein (the “Securities Purchase
Agreement”).

1. EXERCISE OF WARRANT.

(a) Mechanics of Exercise. Subject to the terms and conditions hereof (including,
without limitation, the limitations set forth in Section 1(e) and the conditions set forth in the
Exercise Notice (as defined below)), this Warrant may be exercised by the Holder on any day on or
after the Issuance Date, in whole or in part, by (i) delivery of a written notice, in the form
attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise
this Warrant and (ii) payment to the Company of an amount equal to the applicable Exercise Price
multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the
"Aggregate Exercise Price”) in cash or wire transfer of immediately available funds. The Holder
shall not be required to deliver the original Warrant in order to effect an exercise hereunder.
Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares
shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant
evidencing the right to purchase the remaining number of Warrant Shares. On or before the first
Business Day following the date on which the Company has received each of the Exercise Notice and
the Aggregate Exercise Price (the “Exercise Delivery Documents”), the Company shall transmit by
facsimile an acknowledgment of confirmation of receipt of the Exercise Delivery Documents to the
Holder and the Company’s transfer agent (the “Transfer Agent”). On or before the third Business
Day following the date on which the Company has received all of the Exercise Delivery Documents
(the “Share Delivery Date”), the Company shall (X) provided that the Transfer Agent is
participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program,
upon the request of the Holder, credit such aggregate number of Common Shares to which the Holder
is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC
through its Deposit Withdrawal Agent Commission system, or (Y) if the foregoing shall not apply,
issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a
certificate, registered in the Company’s share register in the name of the Holder or its designee,
for the number of Common Shares to which the Holder is entitled pursuant to such exercise. Upon
delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has
been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant
Shares. If this Warrant is submitted in connection with any exercise pursuant to this Section 1(a)
and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than
the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as
practicable and in no event later than three (3) Business Days after any exercise and at its own
expense, issue a new Warrant (in accordance with Section 7(d)) representing the right to purchase
the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant,
less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional
Common Shares are to be issued upon the exercise of this Warrant, but rather the number of Common
Shares to be issued shall be rounded up to the nearest whole number. The Warrant Shares shall bear
the legends referred to in Sections 2(g) of the Securities Purchase Agreement, to the extent
required thereby.

(b) Exercise Price. For purposes of this Warrant, “Exercise Price” means CDN$1.16,
subject to adjustment as provided herein.

(c) Company’s Failure to Timely Deliver Securities. If within three (3) Trading Days
(as defined in the SPA Securities) after the Company’s receipt of the facsimile copy of a Exercise
Notice the Company shall fail to issue and deliver a certificate to the Holder and register such
Common Shares on the Company’s share register or credit the Holder’s balance account with DTC for
the number of Common Shares to which the Holder is entitled upon such holder’s exercise hereunder,
and if on or after such Trading Day the Holder purchases (in an open market transaction or
otherwise) Common Shares to deliver in satisfaction of a sale by the Holder of Common Shares
issuable upon such exercise that the Holder anticipated receiving from the Company (a “Buy-In"),
then the Company shall, within three (3) Business Days after the Holder’s request and in the
Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total
purchase price (including brokerage commissions, if any) for the Common Shares so purchased (the
“Buy-In Price"), at which point the Company’s obligation to deliver such certificate (and to issue
such Common Shares) shall terminate, or (ii) promptly honor its obligation to deliver to the Holder
a certificate or certificates representing such Common Shares and pay cash to the Holder in an
amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of
Common Shares, times (B) the Closing Bid Price on the date of exercise.

(d) Disputes. In the case of a dispute as to the determination of the Exercise Price
or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder
the number of Warrant Shares that are not disputed and resolve such dispute in accordance with
Section 15.

(e) Limitation on Exercises.

(i) Beneficial Ownership. Notwithstanding anything
contained herein to the contrary, the Company shall not effect any
exercise of this Warrant, and the Holder shall not have the right to
exercise any portion this Warrant, that would be exercisable for that
number of Common Shares which, when added to the number of Common
Shares otherwise beneficially owned by the Holder including those
issuable upon the exercise of convertible securities, warrants or
options held by the Holder, would exceed 4.99% (the “Maximum
Percentage”) of the outstanding Common Shares at the time of
conversion. For purposes of this paragraph, beneficial ownership
shall be calculated in accordance with Section 13(d) of the
Securities Exchange Act of 1934, as amended. For purposes of this
Warrant, in determining the number of outstanding Common Shares, the
Holder may rely on the number of outstanding Common Shares as
reflected in (1) the Company’s most recent Form 20-F, Current Report
on Form 6-K or other public filing with the Securities and Exchange
Commission or the Canadian Securities Administration, as the case may
be, (2) a more recent public announcement by the Company or (3) any
other notice by the Company or the Transfer Agent setting forth the
number of Common Shares outstanding. For any reason at any time,
upon the written request of the Holder, the Company shall within one
Business Day of receipt of a written request from the Holder confirm
in writing to the Holder the number of Common Shares then
outstanding. In any case, the number of outstanding Common Shares
shall be determined after giving effect to the conversion or exercise
of securities of the Company, including the SPA Securities and the
SPA Warrants, by the Holder and its affiliates since the date as of
which such number of outstanding Common Shares was reported. By
written notice to the Company, the Holder may increase or decrease
the Maximum Percentage to any other percentage not in excess of 9.99%
specified in such notice; provided that (i) any such increase will
not be effective until the sixty-first (61st) day after
such notice is delivered to the Company, and (ii) any such increase
or decrease will apply only to the Holder and not to any other holder
of SPA Securities.

(ii) Principal Market Regulation. The Company shall not
be obligated to issue any Common Shares upon exercise of this Warrant
if the issuance of such Common Shares would exceed that number of
Common Shares which the Company may issue upon exercise of this
Warrant (including, as applicable, any Common Shares issued upon
conversion or exercise of the SPA Securities) without breaching the
Company’s obligations under the rules or regulations of the Principal
Market (the “Exchange Cap”). The Company shall seek the approval of
the Principal Market, and shall seek the approval of its shareholders
as may be required by the applicable rules of the Principal Market,
for issuances of Common Shares in excess of the Exchange Cap. Once
the Company has obtained the approval or approvals required by the
foregoing sentence, the Exchange Cap shall no longer be applicable.
Until such approval is obtained, no Buyer shall be issued, upon
exercise or conversion, as applicable, of any SPA Warrants or SPA
Securities, Common Shares in an amount greater than the product of
the Exchange Cap multiplied by a fraction, the numerator of which is
the total number of Common Shares issued to such Buyer pursuant to
the Securities Purchase Agreement on the Issuance Date and the
denominator of which is the aggregate number of Common Shares issued
to the Buyers pursuant to the Securities Purchase Agreement on the
Issuance Date (with respect to each Buyer, the “Exchange Cap
Allocation”). In the event that any Buyer shall sell or otherwise
transfer any of such Buyer’s SPA Warrants, the transferee shall be
allocated a pro rata portion of such Buyer’s Exchange Cap Allocation,
and the restrictions of the prior sentence shall apply to such
transferee with respect to the portion of the Exchange Cap Allocation
allocated to such transferee. In the event that any holder of SPA
Warrants shall exercise all of such holder’s SPA Warrants into a
number of Common Shares which, in the aggregate, is less than such
holder’s Exchange Cap Allocation, then the difference between such
holder’s Exchange Cap Allocation and the number of Common Shares
actually issued to such holder shall be allocated to the respective
Exchange Cap Allocations of the remaining holders of SPA Warrants on
a pro rata basis in proportion to the Common Shares underlying the
SPA Warrants then held by each such holder. In the event that the
Company is prohibited from issuing any Warrant Shares for which an
Exercise Notice has been received as a result of the operation of
this Section 1(e)(ii), the Company shall pay cash in exchange for
cancellation of such Warrant Shares, at a price per Warrant Share
equal to the difference between the Closing Sale Price and the
Exercise Price as of the date of the attempted exercise.

2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and
the number of Warrant Shares shall be adjusted from time to time as follows:

(a) Adjustment upon Issuance of Common Shares. If and whenever on or before the first
anniversary of the Subscription Date the Company issues or sells, or in accordance with this
Section 2 is deemed to have issued or sold, any Common Shares (including the issuance or sale of
Common Shares owned or held by or for the account of the Company, but excluding Common Shares
deemed to have been issued by the Company in connection with any Excluded Securities (as defined in
the SPA Securities) for a consideration per share (the “New Issuance Price”) less than a price (the
"Applicable Price”) equal to the Exercise Price in effect immediately prior to such issue or sale
or deemed issuance or sale (the foregoing a “Dilutive Issuance"), then immediately after such
Dilutive Issuance, the Exercise Price then in effect shall be reduced to the New Issuance Price.
Upon each such adjustment of the Exercise Price hereunder, the number of Warrant Shares shall be
adjusted to the number of Common Shares determined by multiplying the Exercise Price in effect
immediately prior to such adjustment by the number of Warrant Shares acquirable upon exercise of
this Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise
Price resulting from such adjustment. For purposes of determining the adjusted Exercise Price
under this Section 2(a), the following shall be applicable:

(i) Issuance of Options. If the Company in any manner grants
any Options and the lowest price per share for which one Common Share is
issuable upon the exercise of any such Option or upon conversion, exercise
or exchange of any Convertible Securities issuable upon exercise of any such
Option is less than the Applicable Price, then such Common Share shall be
deemed to be outstanding and to have been issued and sold by the Company at
the time of the granting or sale of such Option for such price per share.
For purposes of this Section 2(a)(i), the “lowest price per share for which
one Common Share is issuable upon exercise of such Options or upon
conversion, exercise or exchange of such Convertible Securities” shall be
equal to the sum of the lowest amounts of consideration (if any) received or
receivable by the Company with respect to any one Common Share upon the
granting or sale of the Option, upon exercise of the Option and upon
conversion, exercise or exchange of any Convertible Security issuable upon
exercise of such Option. No further adjustment of the Exercise Price or
number of Warrant Shares shall be made upon the actual issuance of such
Common Shares or of such Convertible Securities upon the exercise of such
Options or upon the actual issuance of such Common Shares upon conversion,
exercise or exchange of such Convertible Securities.

(ii) Issuance of Convertible Securities. If the Company in any
manner issues or sells any Convertible Securities and the lowest price per
share for which one Common Share is issuable upon the conversion, exercise
or exchange thereof is less than the Applicable Price, then such Common
Share shall be deemed to be outstanding and to have been issued and sold by
the Company at the time of the issuance or sale of such Convertible
Securities for such price per share. For the purposes of this Section
2(a)(ii), the “lowest price per share for which one Common Share is issuable
upon the conversion, exercise or exchange” shall be equal to the sum of the
lowest amounts of consideration (if any) received or receivable by the
Company with respect to one Common Share upon the issuance or sale of the
Convertible Security and upon conversion, exercise or exchange of such
Convertible Security. No further adjustment of the Exercise Price or number
of Warrant Shares shall be made upon the actual issuance of such Common
Shares upon conversion, exercise or exchange of such Convertible Securities,
and if any such issue or sale of such Convertible Securities is made upon
exercise of any Options for which adjustment of this Warrant has been or is
to be made pursuant to other provisions of this Section 2(a), no further
adjustment of the Exercise Price or number of Warrant Shares shall be made
by reason of such issue or sale.

(iii) Change in Option Price or Rate of Conversion. If the
purchase price provided for in any Options, the additional consideration, if
any, payable upon the issue, conversion, exercise or exchange of any
Convertible Securities, or the rate at which any Convertible Securities are
convertible into or exercisable or exchangeable for Common Shares increases
or decreases at any time, the Exercise Price and the number of Warrant
Shares in effect at the time of such increase or decrease shall be adjusted
to the Exercise Price and the number of Warrant Shares which would have been
in effect at such time had such Options or Convertible Securities provided
for such increased or decreased purchase price, additional consideration or
increased or decreased conversion rate, as the case may be, at the time
initially granted, issued or sold. For purposes of this Section 2(a)(iii),
if the terms of any Option or Convertible Security that was outstanding as
of the date of issuance of this Warrant are increased or decreased in the
manner described in the immediately preceding sentence, then such Option or
Convertible Security and the Common Shares deemed issuable upon exercise,
conversion or exchange thereof shall be deemed to have been issued as of the
date of such increase or decrease. No adjustment pursuant to this Section
2(a) shall be made if such adjustment would result in an increase of the
Exercise Price then in effect or a decrease in the number of Warrant Shares.

(iv) Calculation of Consideration Received. In case any Option
is issued in connection with the issue or sale of other securities of the
Company, together comprising one integrated transaction in which no specific
consideration is allocated to such Options by the parties thereto, the
Options will be deemed to have been issued for a consideration of $0.01. If
any Common Shares, Options or Convertible Securities are issued or sold or
deemed to have been issued or sold for cash, the consideration received
therefor will be deemed to be the net amount received by the Company
therefor. If any Common Shares, Options or Convertible Securities are
issued or sold for a consideration other than cash, the amount of such
consideration received by the Company will be the fair value of such
consideration, except where such consideration consists of securities, in
which case the amount of consideration received by the Company will be the
Closing Sale Price of such security on the date of receipt. If any Common
Shares, Options or Convertible Securities are issued to the owners of the
non-surviving entity in connection with any merger in which the Company is
the surviving entity, the amount of consideration therefor will be deemed to
be the fair value of such portion of the net assets and business of the
non-surviving entity as is attributable to such Common Shares, Options or
Convertible Securities, as the case may be. The fair value of any
consideration other than cash or securities will be determined jointly by
the Company and the Required Holders. If such parties are unable to reach
agreement within ten (10) days after the occurrence of an event requiring
valuation (the “Valuation Event”), the fair value of such consideration will
be determined within five (5) Business Days after the tenth day following
the Valuation Event by an independent, reputable appraiser jointly selected
by the Company and the Required Holders. The determination of such
appraiser shall be final and binding upon all parties absent manifest error
and the fees and expenses of such appraiser shall be borne by the Company.

(v) Record Date. If the Company takes a record of the holders
of Common Shares for the purpose of entitling them (A) to receive a dividend
or other distribution payable in Common Shares, Options or in Convertible
Securities or (B) to subscribe for or purchase Common Shares, Options or
Convertible Securities, then such record date will be deemed to be the date
of the issue or sale of the Common Shares deemed to have been issued or sold
upon the declaration of such dividend or the making of such other
distribution or the date of the granting of such right of subscription or
purchase, as the case may be.

(b) Adjustment upon Subdivision or Combination of Common Shares. If the Company at
any time on or after the Subscription Date subdivides (by any share split, share dividend,
recapitalization or otherwise) one or more classes of its outstanding Common Shares into a greater
number of shares, the Exercise Price in effect immediately prior to such subdivision will be
proportionately reduced and the number of Warrant Shares will be proportionately increased. If the
Company at any time on or after the Subscription Date combines (by combination, reverse share
split or otherwise) one or more classes of its outstanding Common Shares into a smaller number of
shares, the Exercise Price in effect immediately prior to such combination will be proportionately
increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under
this Section 2(b) shall become effective at the close of business on the date the subdivision or
combination becomes effective.

(c) Other Events. If any event occurs of the type contemplated by the provisions of
this Section 2 but not expressly provided for by such provisions (including, without limitation,
the granting of share appreciation rights, phantom share rights or other rights with equity
features), then the Company’s Board of Directors will make an appropriate adjustment in the
Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided
that no such adjustment pursuant to this Section 2(c) will increase the Exercise Price or decrease
the number of Warrant Shares as otherwise determined pursuant to this Section 2.

3. RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common
Shares, by way of return of capital or otherwise (including, without limitation, any distribution
of cash, shares or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
"Distribution”), at any time after the issuance of this Warrant, then, in each such case the
Exercise Price in respect of Warrants not exercised on or prior to the close of business on the
record date fixed for the determination of holders of Common Shares entitled to receive the
Distribution shall be reduced, effective as of the close of business on such record date, to a
price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall
be the arithmetic average of the Weighted Average Price (as defined in the SPA Securities) of the
Common Shares for the 10 Trading Days immediately preceding such record date minus the value of the
Distribution (as determined in good faith by the Company’s Board of Directors) applicable to one
Common Share, and (ii) the denominator shall be the arithmetic average of the Weighted Average
Price (as defined in the SPA Securities) of the Common Shares for the 10 Trading Days immediately
preceding such record date.

4. PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.

(a) Purchase Rights. In addition to any adjustments pursuant to Section 2 above, if
at any time the Company grants, issues or sells any Options, Convertible Securities or rights to
purchase shares, warrants, securities or other property pro rata to all of the record holders of
any class of Common Shares (the “Purchase Rights”), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights and in lieu of any adjustments to which the
Holder is otherwise entitled under Section 3 above in respect of such Purchase Rights, the
aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of
Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations
on the exercise of this Warrant) immediately before the date on which a record is taken for the
grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of
which the record holders of Common Shares are to be determined for the grant, issue or sale of such
Purchase Rights.

(b) Fundamental Transactions. The Company shall not enter into or be party to a
Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations
of the Company under this Warrant and the other Transaction Documents in accordance with the
provisions of this Section (4)(b) pursuant to written agreements in form and substance satisfactory
to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction,
including agreements to deliver to each holder of Warrants in exchange for such Warrants a security
of the Successor Entity evidenced by a written instrument substantially similar in form and
substance to this Warrant, including, without limitation, an adjusted exercise price equal to the
value for the Common Shares reflected by the terms of such Fundamental Transaction, and exercisable
for a corresponding number of shares of capital shares equivalent to the Common Shares acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of
this Warrant) prior to such Fundamental Transaction, and satisfactory to the Required Holders and
(ii) subject to Section 4(c) below, the Successor Entity is a publicly traded corporation whose
common shares are quoted on or listed for trading on an Eligible Market (a “Public Successor”).
Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be
substituted for (so that from and after the date of such Fundamental Transaction, the provisions of
this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may
exercise every right and power of the Company and shall assume all of the obligations of the
Company under this Warrant with the same effect as if such Successor Entity had been named as the
Company herein. Upon consummation of the Fundamental Transaction, the Successor Entity shall
deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any
time after the consummation of the Fundamental Transaction, in lieu of the shares of the Common
Shares (or other securities, cash, assets or other property) purchasable upon the exercise of the
Warrant prior to such Fundamental Transaction, such shares, securities, cash, assets or any other
property whatsoever (including warrants or other purchase or subscription rights) which the Holder
would have been entitled to receive upon the happening of such Fundamental Transaction had this
Warrant been converted immediately prior to such Fundamental Transaction, as adjusted in accordance
with the provisions of this Warrant. In addition to and not in substitution for any other rights
hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of
Common Shares are entitled to receive securities or other assets with respect to or in exchange for
Common Shares (a “Corporate Event”), the Company shall make appropriate provision to insure that
the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time
after the consummation of the Fundamental Transaction but prior to the Expiration Date, in lieu of
the shares of the Common Shares (or other securities, cash, assets or other property) purchasable
upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of shares,
securities, cash, assets or any other property whatsoever (including warrants or other purchase or
subscription rights) which the Holder would have been entitled to receive upon the happening of
such Fundamental Transaction had the Warrant been exercised immediately prior to such Fundamental
Transaction; provided, however, that in the event that, pursuant to the terms of the Fundamental
Transaction, the holders of Common Shares may elect the consideration to be received in exchange
for the Common Shares in the such Fundamental Transaction, the Holder shall elect, within the same
time periods as provided to the holders of Common Shares, the kind or amount of such shares,
securities, cash, assets or any other property (including warrants or other purchase or
subscription rights) that the Holder will, following the consummation of such transaction, be
entitled to receive upon exercise; provided, further, however, that no such election by the Holder
shall be construed to require the exercise of this Warrant in connection with such Fundamental
Transaction. If the Holder is required to make any election of the kind described in the foregoing
sentence, the Company shall deliver to the Holder all documentation, informational materials and
election forms relating to such Fundamental Transaction contemporaneously with the delivery of such
documentation, materials and forms to the holders of the Common Shares. Provision made pursuant to
the preceding sentence shall be in a form and substance reasonably satisfactory to the Required
Holders. The provisions of this Section shall apply similarly and equally to successive
Fundamental Transactions and Corporate Events and shall be applied without regard to any
limitations on the exercise of this Warrant.

(c) Notwithstanding the foregoing and the provisions of Section 4(b) above, in the event of a
Fundamental Transaction where the Successor Entity (and not the Parent Entity) is not a Public
Successor, if the Holder has not exercised the Warrant in full prior to the consummation of the
Fundamental Transaction, then the Company may enter into a Fundamental Transaction pursuant to
which the Holder shall receive, simultaneously with the consummation of the Fundamental
Transaction, in lieu of the warrant referred to in Section 4(b) cash in an amount equal to the
value of the remaining unexercised portion of this Warrant on the date of such consummation, which
value shall be determined by use of the Black and Scholes Option Pricing Model reflecting (i) a
risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining
term of this Warrant as of such date of request and (ii) an expected volatility equal to the
greater of 60% and the 100 day volatility obtained from the HVT function on Bloomberg.

5. NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will
not, by amendment of its Articles of Incorporation, Bylaws or through any reorganization, transfer
of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, and will at all times in good faith carry out all the provisions of this
Warrant and take all action as may be required to protect the rights of the Holder. Without
limiting the generality of the foregoing, the Company (i) shall take all such actions as may be
reasonably necessary or appropriate in order that the Company may validly and legally issue fully
paid and non-assessable Common Shares upon the exercise of this Warrant, and (ii) shall, so long as
any of the SPA Warrants are outstanding, take all reasonable action necessary to reserve and keep
available out of its authorized and unissued Common Shares, solely for the purpose of effecting the
exercise of the SPA Warrants, the requisite number of Common Shares as shall from time to time be
necessary to effect the exercise of the SPA Warrants then outstanding (without regard to any
limitations on exercise).

6. WARRANT HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically
provided herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall
not be entitled to vote or receive dividends or be deemed the holder of share capital of the
Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon
the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a
shareholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of shares, reclassification of shares, consolidation, merger,
conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or
otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then
entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this
Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this
Section 6, the Company shall provide the Holder with copies of the same notices and other
information given to the shareholders of the Company generally, contemporaneously with the giving
thereof to the shareholders.

7. REISSUANCE OF WARRANTS.

(a) Transfer of Warrant. If this Warrant is to be transferred, the Holder shall
surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon
the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder
may request, representing the right to purchase the number of Warrant Shares being transferred by
the Holder and, if less then the total number of Warrant Shares then underlying this Warrant is
being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the
right to purchase the number of Warrant Shares not being transferred.

(b) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the
Holder to the Company in customary form and, in the case of mutilation, upon surrender and
cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in
accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying
this Warrant.

(c) Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the
surrender hereof by the Holder at the principal office of the Company, for a new Warrant or
Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the
number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the
right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of
such surrender; provided, however, that no Warrants for fractional Common Shares shall be given.

(d) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant
pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this
Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase
the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued
pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when
added to the number of Common Shares underlying the other new Warrants issued in connection with
such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii)
shall have an issuance date, as indicated on the face of such new Warrant which is the same as the
Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

8. NOTICES. Whenever notice is required to be given under this Warrant, unless
otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the
Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of
all actions taken pursuant to this Warrant, including in reasonable detail a description of such
action and the reason therefore. Without limiting the generality of the foregoing, the Company
will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price,
setting forth in reasonable detail, the calculation of such adjustment and (ii) at least seven days
prior to the date on which the Company closes its books or takes a record (A) with respect to any
dividend or distribution upon the Common Shares, (B) with respect to any grants, issuances or sales
of any Options, Convertible Securities or rights to purchase shares, warrants, securities or other
property to all holders of Common Shares or (C) for determining rights to vote with respect to any
Fundamental Transaction, dissolution or liquidation, provided in each case that such information
shall be made known to the public prior to or in conjunction with such notice being provided to the
Holder.

9. AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this
Warrant may be amended and the Company may take any action herein prohibited, or omit to perform
any act herein required to be performed by it, only if the Company has obtained the written consent
of the Required Holders; provided that no such action may increase the exercise price of any SPA
Warrant or decrease the number of shares or class of shares obtainable upon exercise of any SPA
Warrant without the written consent of the Holder. No such amendment shall be effective to the
extent that it applies to less than all of the holders of the SPA Warrants then outstanding.

10. GOVERNING LAW. This Warrant shall be governed by and construed and enforced in
accordance with, and all questions concerning the construction, validity, interpretation and
performance of this Warrant shall be governed by, the internal laws of the State of New York,
without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of New York or any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of New York. Any action brought by either party against the
other concerning the transactions contemplated by this Agreement shall be brought only in the state
courts of New York or in the federal courts located in the State of New York and waive trial by
jury. Both parties agree to submit to the jurisdiction of such courts. The prevailing party shall
be entitled to recover from the other party its reasonable attorney’s fees and costs. In the event
that any provision of this Warrant is invalid or unenforceable under any applicable statute or rule
of law, then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any such
provision which may prove invalid or unenforceable under any law shall not affect the validity or
enforceability of any other provision of this Warrant. Nothing contained herein shall be deemed or
operate to preclude the Holder from bringing suit or taking other legal action against the Company
in any other jurisdiction to collect on the Company’s obligations to the Holder, to realize on any
collateral or any other security for such obligations, or to enforce a judgment or other court
ruling in favour of the Holder.

11. JUDGMENT CURRENCY.

(a) If for the purpose of obtaining or enforcing judgment against the Company in any court in
any jurisdiction it becomes necessary to convert into any other currency (such other currency being
hereinafter in this Section 11 referred to as the “Judgment Currency”) an amount due in US dollars
under this Warrant, the conversion shall be made at the Exchange Rate prevailing on the business
day immediately preceding:

(i) the date actual payment of the amount due, in the case of any
proceeding in the courts of New York or in the courts of any other
jurisdiction that will give effect to such conversion being made on
such date: or

(ii) the date on which the foreign court determines, in the case of
any proceeding in the courts of any other jurisdiction (the date as
of which such conversion is made pursuant to this Section 11(a)(ii)
being hereinafter referred to as the “Judgment Conversion Date”).

(b) If in the case of any proceeding in the court of any jurisdiction referred to in Section
11(a)(ii) above, there is a change in the Exchange Rate prevailing between the Judgment Conversion
Date and the date of actual payment of the amount due, the applicable party shall pay such adjusted
amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted
at the Exchange Rate prevailing on the date of payment, will produce the amount of US dollars which
could have been purchased with the amount of Judgment Currency stipulated in the judgment or
judicial order at the Exchange Rate prevailing on the Judgment Conversion Date.

(c) Any amount due from the Company under this provision shall be due as a separate debt and
shall not be affected by judgment being obtained for any other amounts due under or in respect of
this Warrant.

12. CURRENCY. All amounts owing under this Warrant or any Transaction Document that,
in accordance with their terms, are paid in cash shall be paid in US dollars. All amounts
denominated in other currencies shall be converted in the US dollar equivalent amount in accordance
with the Exchange Rate on the date of calculation (for the purpose of Section 2 hereof, the date of
calculation shall equal the date of such event resulting in the adjustment of the Exercise Price
thereunder). “Exchange Rate” means, in relation to any amount of currency to be converted into US
dollars pursuant to this Warrant, the US dollar exchange rate as published in the Wall Street
Journal on the relevant date of calculation.

13. TAXES.

(a) Any and all payments by the Company hereunder, including any amounts received on an
exercise of this Warrant and any amounts on account of interest or deemed interest, shall be made
free and clear of and without deduction for any and all present or future taxes, levies, imposts,
deductions, charges or withholdings, and all liabilities with respect thereto, imposed under Part
XIII of the Income Tax Act (Canada) (collectively referred to as “Part XIII Taxes”). If the
Company shall be required to deduct any Part XIII Taxes from or in respect of any sum payable
hereunder to the Holder, (i) the sum payable shall be increased by one-half of the amount by which
the sum payable would otherwise have to be increased (the “make-whole amount”) to ensure that after
making all required deductions (including deductions applicable to the make-whole amount) the
Holder would receive an amount equal to the sum it would have received had no such deductions been
made, (ii) the Company shall make such deductions and (iii) the Company shall pay the full amount
withheld or deducted to the Canada Revenue Agency within the time required. For example, assuming
that the Company is required to deduct 25% of a $100 interest payment hereunder, the Company shall
be required to increase such payment by $16.67.

(b) In addition, the Company agrees to pay to the relevant governmental authority in
accordance with applicable law any present or future stamp or documentary taxes or any other excise
or property taxes, charges or similar levies that arise from any payment made hereunder or in
connection with the execution, delivery, registration or performance of, or otherwise with respect
to, this Warrant (“Other Taxes”). The Company shall deliver to the Holder official receipts, if
any, in respect of any Part XIII Taxes and Other Taxes payable hereunder promptly after payment of
such Part XIII Taxes, Other Taxes or other evidence of payment reasonably acceptable to the Holder.

(c) The obligations of the Company under this Section 13(c) shall survive the termination of
this Warrant and the exercise of this Warrant and all other amounts payable hereunder.

14. MAXIMUM PAYMENTS. Nothing contained herein shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by
applicable law. In the event that the rate of interest required to be paid or other charges
hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be
credited against amounts owed by the Company to the Holder and thus refunded to the Company.

15. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the
Company and all the Buyers and shall not be construed against any person as the drafter hereof.
The headings of this Warrant are for convenience of reference and shall not form part of, or affect
the interpretation of, this Warrant.

16. DISPUTE RESOLUTION. In the case of a dispute as to the determination of the
Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the
disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of
receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If
the Holder and the Company are unable to agree upon such determination or calculation of the
Exercise Price or the Warrant Shares within three (3) Business Days of such disputed determination
or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2)
Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an
independent, reputable investment bank selected by the Company and approved by the Holder or (b)
the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside
accountant. The Company shall cause at its expense the investment bank or the accountant, as the
case may be, to perform the determinations or calculations and notify the Company and the Holder of
the results no later than ten (10) Business Days from the time it receives the disputed
determinations or calculations. Such investment bank’s or accountant’s determination or
calculation, as the case may be, shall be binding upon all parties absent demonstrable error. In
the event the Company’s determination or calculation is correct, the expenses of the investment
bank or accountant, as the case may be, shall be borne by the Holder.

17. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies
provided in this Warrant shall be cumulative and in addition to all other remedies available under
this Warrant and the other Transaction Documents, at law or in equity (including a decree of
specific performance and/or other injunctive relief), and nothing herein shall limit the right of
the Holder right to pursue actual damages for any failure by the Company to comply with the terms
of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will
cause irreparable harm to the Holder and that the remedy at law for any such breach may be
inadequate. The Company therefore agrees that, in the event of any such breach or threatened
breach, the holder of this Warrant shall be entitled, in addition to all other available remedies,
to an injunction restraining any breach, without the necessity of showing economic loss and without
any bond or other security being required.

18. TRANSFER. This Warrant may be offered for sale, sold, transferred or assigned
without the consent of the Company, except as may otherwise be required by Section 2(f) of the
Securities Purchase Agreement.

19. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have
the following meanings:

(a) "Bloomberg” means Bloomberg Financial Markets.

(b) "Business Day” means any day other than Saturday, Sunday or other day on which commercial
banks in The City of New York are authorized or required by law to remain closed.

(c) "Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the
last closing bid price and last closing trade price, respectively, for such security on the
Principal Market, as reported by Bloomberg or by the Principal Market, or, if the Principal Market
begins to operate on an extended hours basis and does not designate the closing bid price or the
closing trade price, as the case may be, then the last bid price or last trade price, respectively,
of such security prior to 4:00:00 p.m., New York Time, as reported by Bloomberg or by the Principal
Market, or, if the Principal Market is not the principal securities exchange or trading market for
such security, the last closing bid price or last trade price, respectively, of such security on
the principal securities exchange or trading market where such security is listed or traded as
reported by Bloomberg or by the Principal Market, or if the foregoing do not apply, the last
closing bid price or last trade price, respectively, of such security in the over-the-counter
market on the electronic bulletin board for such security as reported by Bloomberg or by the
Principal Market, or, if no closing bid price or last trade price, respectively, is reported for
such security by Bloomberg or by the Principal Market, the average of the bid prices, or the ask
prices, respectively, of any market makers for such security as reported in the “pink sheets” by
Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If the Closing Bid Price or the
Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing
bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on
such date shall be the fair market value as mutually determined by the Company and the Holder. If
the Company and the Holder are unable to agree upon the fair market value of such security, then
such dispute shall be resolved pursuant to Section 15. All such determinations to be appropriately
adjusted for any share dividend, share split, share combination or other similar transaction during
the applicable calculation period.

(d) "Common Shares” means (i) the Company’s Common Shares, no par value per share, and (ii)
any share capital into which such Common Shares shall have been changed or any share capital
resulting from a reclassification of such Common Shares.

(e) “Common Shares Deemed Outstanding” means, at any given time, the number of Common Shares
actually outstanding at such time, plus the number of Common Shares deemed to be outstanding
pursuant to Sections 2(a)(i) and 2(a)(ii) hereof regardless of whether the Options or Convertible
Securities are actually exercisable at such time, but excluding any Common Shares owned or held by
or for the account of the Company or issuable upon conversion and exercise, as applicable, of the
SPA Securities and the Warrants.

(f) "Convertible Securities” means any shares or securities (other than Options) directly or
indirectly convertible into or exercisable or exchangeable for Common Shares.

(g) "Eligible Market” means the Principal Market, The New York Stock Exchange, Inc., the
American Stock Exchange, the Nasdaq National Market or The Nasdaq SmallCap Market.

(h) "Expiration Date” means the date sixty (60) months after the Issuance Date or, if such
date falls on a day other than a Business Day or on which trading does not take place on the
Principal Market (a “Holiday”), the next date that is not a Holiday.

(i) "Fundamental Transaction” means that the Company shall, directly or indirectly, in one or
more related transactions, (i) consolidate or merge with or into (whether or not the Company is the
surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose
of all or substantially all of the properties or assets of the Company to another Person, or (iii)
allow another Person to make a purchase, tender or exchange offer that is accepted by the holders
of more than the 50% of the outstanding Common Shares (not including any Common Shares held by the
Person or Persons making or party to, or associated or affiliated with the Persons making or party
to, such purchase, tender or exchange offer), or (iv) consummate a share purchase agreement or
other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than
the 50% of the outstanding Common Shares (not including any Common Shares held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or
party to, such share purchase agreement or other business combination), or (v) reorganize,
recapitalize or reclassify its Common Shares. For the avoidance of doubt, and notwithstanding the
foregoing, the Company may create new Subsidiaries, including trusts the sole trustees of which are
members of the Company’s Board of Directors, and transfer any assets of any kind or nature to
either its existing Subsidiaries or to any new Subsidiaries, and neither the creation of any such
new Subsidiaries nor the transfer of assets to existing or new Subsidiaries shall be deemed a
Fundamental Transaction so long as, concurrently with any such transactions, the Company causes
such existing Subsidiaries or new Subsidiaries to grant a security interest and/or hypothec in
accordance with the security arrangements referenced in Section 10 of the SPA Securities to the
extent required.

(j) "Options” means any rights, warrants or options to subscribe for or purchase Common Shares
or Convertible Securities.

(k) "Parent Entity” of a Person means an entity that, directly or indirectly, controls the
applicable Person and whose common shares or equivalent equity security is quoted or listed on an
Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent
Entity with the largest public market capitalization as of the date of consummation of the
Fundamental Transaction.

(l) "Person” means an individual, a limited liability company, a partnership, a joint venture,
a corporation, a trust, an unincorporated organization, any other entity and a government or any
department or agency thereof.

(m) "Principal Market” means the Toronto Stock Exchange.

(n) "Required Holders” means the holders of the SPA Warrants representing at least a majority
of Common Shares underlying the SPA Warrants then outstanding.

(o) "SPA Securities” means the Notes issued pursuant to the Securities Purchase Agreement.

(p) "Successor Entity” means the Person (or, if so elected by the Required Holders, the Parent
Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so
elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall
have been entered into.

[Signature Page Follows]

1

IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Shares to be
duly executed as of the Issuance Date set out above.

ART ADVANCED RESEARCH TECHNOLOGIES INC.

By:

Name:

Title:

2

EXHIBIT A

EXERCISE NOTICE

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT TO PURCHASE COMMON SHARES

ART ADVANCED RESEARCH TECHNOLOGIES INC.

The undersigned holder hereby exercises the right to purchase      of the
Common Shares (“Warrant Shares”) of ART Advanced Research Technologies Inc., a Canadian corporation
(the “Company”), evidenced by the attached Warrant to Purchase Common Shares (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set
forth in the Warrant.

1. Payment of Exercise Price. The holder shall pay the Aggregate Exercise Price in the sum
of $     to the Company in accordance with the terms of the Warrant.

2. Delivery of Warrant Shares. The Company shall deliver to the holder      Warrant
Shares to      1in accordance with the terms of the Warrant.

Notwithstanding anything to the contrary contained herein, this Exercise Notice shall
constitute a representation and warranty by the undersigned that, after giving effect to the
exercise provided for in this Exercise Notice, the undersigned (together with its affiliates) will
not have beneficial ownership (together with the beneficial ownership of such Person’s affiliates)
of a number of Common Shares which exceeds the Maximum Percentage. It shall also constitute a
representation and warranty by the undersigned that all of the representations and warranties set
forth in Section 2 of the Securities Purchase Agreement, modified as if all of the references
therein to the Notes and Warrants were references to Warrant Shares, are true and correct as of the
date hereof.

Date:      ,      

Name of Registered Holder

By:

Name:

Title:

1 To insert account of holder for delivery of
Warrant Shares.

3

ACKNOWLEDGMENT

The Company hereby acknowledges this Exercise Notice and hereby directs National Bank Trust to
issue the above indicated number of Common Shares in accordance with the Transfer Agent
Instructions dated July 28, 2005 from the Company and acknowledged and agreed to by National Bank
Trust.

ART ADVANCED RESEARCH TECHNOLOGIES INC.

By:

Name:

Title:

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]